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Tuberculosis (TB) is a	  global epidemic that has proved difficult to control due to the characteristics of
theMycobacterium tuberculosis bacillus.	  It is a slow-­‐growing	  disease with a long delay between
infection	  and	  the	  manifestation of symptoms, thus the infectious pool in	  the community is large,
perpetuating transmission.
Furthermore, high-­‐risk groups for	  developing active TB such as	  people living with the human
immunodeficiency	  virus	  (HIV),	  those	  who have diabetes mellitus (DM) or those who	  smoke cigarettes	  
have a much	  higher risk of contracting TB	  than	  the rest of the population	  and	  warrant intensified	  
screening for TB.
In	  addition,	  TB cases with these additional influences may manifest their symptoms differently.
Finding and treating cases	  in	  the	  community before they present to	  health	  facilities,	  a	  strategy
known as active-­‐case-­‐finding, is gaining momentum as a way to decrease the infectious pool. This
can be achieved through door to door community	  surveys	  using	  a TB symptom-­‐screening
questionnaire, and is	  an	  economical	  and	  practical	  tool	  to	  employ	  in	  poor,	  high	  burden	  areas.	  	  
However, unlike for the high risk group of people	  infected with HIV, there is a lack of	  evidence
supporting the adaptation	  of a symptom screening tool in	  other high	  risk groups.
In	  2010,	  a	  TB	  prevalence	  survey was conducted in 24 high TB and HIV burden communities	  in Zambia
and the	  Western Cape, South Africa. This prevalence survey served	  as the endpoint for the Zambia
South Africa TB	  and	  AIDS Reduction	  study (ZAMSTAR).
This survey made use of a	  questionnaire that collected, among other information, data	  regarding
individual	  TB symptom reporting, HIV status, diabetes mellitus status and cigarette smoking.
Consenting participants were	  also encouraged to provide	  sputum samples for TB confirmation
through 16s DNA sequencing, and blood samples for	  rapid HIV testing and glucose measurements.
The data	  from this survey provided an opportunity to investigate the differences in symptom	  
reporting between bacteriologically confirmed TB cases and TB cases with the additional influences
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  INTRODUCTION	  
	  
Symptom	  screening	  for	  tuberculosis	  (TB)	  is	  accepted	  as	  an	  effective	  tool	  to	  actively	  detect	  
suspect	  TB	  cases	  who	  would	  benefit	  from	  confirmatory	  testing.(1,2)	  Recently,	  as	  part	  of	  the	  “3	  
I’s”	  initiative,	  TB	  case	  detection	  is	  moving	  from	  the	  established	  strategy	  of	  passive	  detection	  to	  
active,	  or	  intensified,	  TB	  case-­‐finding	  in	  people	  living	  with	  the	  human	  immunodeficiency	  virus	  
(HIV).	  (3)	  While	  intensified	  case-­‐finding	  has	  initially	  been	  promoted	  as	  an	  active	  case-­‐finding	  
strategy	  in	  HIV	  infected	  clients,	  there	  is	  a	  lack	  of	  knowledge	  directing	  symptom-­‐screening	  
strategies	  for	  active	  detection	  of	  TB	  cases	  with	  co-­‐morbidities	  other	  than	  HIV.(4)	  The	  high	  
prevalence	  of	  HIV,	  diabetes	  mellitus,	  and	  smoking	  in	  the	  general	  population,	  may	  impact	  on	  the	  
classical	  presentations	  of	  TB	  and	  therefore	  on	  the	  effectiveness	  of	  a	  symptom	  screening	  tool	  to	  
detect	  TB	  suspects.	  (4–6)	  This	  proposal	  aims	  to	  analyse	  data	  from	  a	  prevalence	  survey	  in	  8	  high	  
burden	  TB	  communities	  in	  Cape	  Town,	  South	  Africa.	  	  The	  analysis	  aims	  to	  determine	  the	  
prevalence	  of,	  and	  differences	  in,	  reported	  TB	  symptoms	  in	  respondents	  according	  to	  














The	  World	  Health	  Organisation	  (WHO)	  reports	  9.4	  million	  incident	  and	  14	  million	  prevalent	  
tuberculosis	  (TB)	  cases	  in	  2009,	  and,	  that	  tuberculosis	  remains	  one	  of	  the	  leading	  causes	  of	  global	  
mortality	  and	  morbidity.(7)
Global	  efforts	  to	  control	  TB	  have	  been	  based	  principally	  on	  case-­‐finding	  and	  treatment	  as	  a	  means	  of	  
decreasing	  transmission	  rates	  and	  incidence	  of	  disease.	  	  Case-­‐finding	  can	  be	  passive	  or	  active.	  	  
Passive	  case-­‐finding	  is	  defined	  as	  detecting	  disease	  in	  patients	  who	  present	  to	  health	  facilities	  with	  
symptoms	  suggestive	  of	  TB.	  Active,	  or	  intensified,	  case-­‐finding	  is	  defined	  as	  actively	  seeking	  
tuberculosis	  diagnosis	  in	  a	  target	  population	  –	  for	  example,	  a	  general	  outpatient	  clinic,	  specific	  
patient	  populations	  at	  high	  risk	  for	  TB,	  or	  the	  general	  community.	  (4,8–10)	  	  
High risk groups for tuberculosis	  include people living with the human immunodeficiency virus	  (HIV),	  
those with diabetes mellitus (DM) and smokers. These	  groups have	  a	  much higher risk of developing
active	  TB compared to the	  general population without	  these additional influences. (11–15)
One of the strategies employed for active case-­‐finding in populations is to use a symptom screening
questionnaire as this has been	  shown	  to	  be an	  “efficient high	  yield	  strategy” in	  resource	  limited
settings	  and is	  a widely accepted screening tool for tuberculosis. (8–10)
However, countries with high-­‐TB burden are also the most resource limited and efforts in active	  case-­‐
finding are thus focused on the vulnerable groups at	  highest	  risk for	  developing active TB. (4,16)
There is a	  substantial amount of literature regarding diagnosis of	  symptomatic TB disease in high HIV
prevalence populations, and	  a lack of literature on	  symptomatic TB	  screening in	  populations with	  
other risk factors such as	  diabetes, and smoking. (4,17) Furthermore, there	  are	  currently only
recommended evidence-­‐based	  guidelines for symptom based	  algorithms for TB	  detection	  in	  the HIV
positive population	  in	  order to	  reliably	  exclude	  TB,	  so	  that	  antiretrovirals	  (ARV) and isoniazid
preventive therapy (IPT) against TB	  can be safely initiated.(4,18)
Symptom-­‐based	  algorithms	  rely	  on	  the	  awareness	  or	  perception	  of	  TB	  symptom-­‐complexes.	  
However,	  additional	  influences	  of	  HIV,	  smoking	  or	  hyperglycaemia	  may	  impact	  on	  the	  reliability	  of	  
self-­‐reporting	  of	  symptoms.	  	  Thus	  the	  effectiveness	  of	  a	  symptom	  screening	  tool	  applied	  to	  any	  
possible	  TB	  case	  in	  the	  community	  may	  be	  affected	  by	  additional	  risk	  factors	  that	  alter	  perceptions	  of	  











In	  2010,	  a	  large	  TB	  prevalence	  survey	  was	  conducted	  in	  24	  high	  TB	  and	  HIV	  burden	  communities	  in	  
South	  Africa	  and	  Zambia,	  which	  served	  as	  the	  primary	  endpoint	  measurement	  for	  the	  three-­‐year	  
Zambia/South	  Africa	  TB	  and	  HIV	  Reduction	  study	  (ZAMSTAR).	  (23)	  
This	  prevalence	  survey	  provides	  a	  unique	  opportunity	  to	  analyse	  the	  differences	  between	  symptom-­‐
reporting	  in	  culture-­‐confirmed	  TB	  cases	  diagnosed	  in	  the	  community	  with	  additional	  influences	  of	  
HIV,	  smoking	  or	  diabetes	  mellitus,	  and	  cases	  that	  do	  not	  have	  these	  additional	  influences.	  	  By	  
analysing	  this	  dataset,	  we	  hope	  to	  add	  to	  the	  evidence	  base	  of	  symptom	  reporting	  in	  high-­‐risk	  groups	  
for	  TB.	  
1. RESEARCH QUESTION
Are	  TB	  cases	  with	  the	  additional	  influences	  of	  smoking,	  HIV	  or	  hyperglycaemia equally	  
likely	  to	  report	  TB	  symptoms	  compared	  to	  TB	  cases	  without	  these	  influences?
2X2	  table:	  
Reported	  Symptoms	  


















H0:	  TB	  cases	  with	  co-­‐morbidities	  are	  equally	  likely	  to	  report	  TB	  symptoms	  compared	  to	  TB	  
cases	  without	  co-­‐morbidities.	  
Ha:	  TB	  cases	  with	  co-­‐morbidities	  are	  not	  equally	  likely	  to	  report	  TB	  symptoms	  compared	  to	  
TB	  cases	  without	  co-­‐morbidities.	  
3. OBJECTIVES	  	  
Objectives	  	  
	  
(1)	  Determine	  the	  prevalence	  of	  hyperglycamiea,	  HIV	  and	  smoking	  amongst	  participants	  of	  
the	  2010	  South	  African	  and	  Zambian	  TB	  prevalence	  survey	  of	  bacteriologically	  confirmed	  TB	  
cases.	  	  
(2)	  Determine	  the	  prevalence	  of	  TB	  symptoms	  in	  bacteriologically	  confirmed	  TB	  cases,	  with	  
or	  without	  co-­‐morbid	  hyperglycaemia,	  HIV-­‐infection,	  or	  concurrent	  smoking.	  	  
(3)	  Determine	  the	  differences	  in	  symptom	  reporting	  when	  screening	  for	  TB	  in	  high	  TB	  burden	  
areas	  where	  a	  high	  proportion	  of	  cases	  also	  smoke	  or	  have	  additional	  influences	  of	  HIV	  
infection	  and	  hyperglycaemia.	  
	  
4. RESEARCH	  DESIGN	  AND	  METHODS	  
Study	  design	  
	  
	  A	  cross-­‐sectional	  study	  design	  will	  be	  employed	  for	  analysis.	  Data	  for	  the	  present	  will	  be	  











Zambia	  and	  South	  Africa,	  as	  part	  of	  the	  Zambia/South	  Africa	  TB	  and	  AIDS	  Reduction	  study	  
(ZAMSTAR).	  
In	  2010	  the	  ZAMSTAR	  TB	  prevalence	  survey	  of	  about	  100	  000	  participants	  was	  conducted	  as	  
a	  joint	  collaboration	  between	  the	  Desmond	  Tutu	  TB	  Centre	  (	  Stellenbosch	  University)	  in	  
Cape	  Town	  South	  Africa,	  ZAMBART	  (University	  of	  Zambia,	  Zambia)	  and	  the	  London	  School	  of	  
Hygiene	  and	  Tropical	  Medicine.	  This	  prevalence	  survey	  was	  conducted	  at	  the	  end	  of	  a	  three	  
year	  TB	  and	  HIV	  intervention	  study	  conducted	  in	  the	  ZAMSTAR	  community	  sites	  throughout	  
Zambia	  and	  South	  Africa.	  
The	  participants	  enrolled	  in	  the	  2010	  Prevalence	  survey	  gave	  written	  informed	  consent	  for	  
questioning	  and	  sputum	  and	  blood	  testing.	  Consent	  forms	  were	  in	  English,	  and	  were	  
translated	  into	  the	  most	  commonly	  spoken	  languages	  in	  the	  community.	  Participants	  read	  
through	  the	  consent	  forms	  and	  were	  encouraged	  to	  ask	  questions	  regarding	  the	  study	  
before	  signing.	  Those	  participants	  who	  could	  not	  read,	  had	  the	  consent	  forms	  read	  to	  them
by	  study	  staff.	  Consented	  participants	  gave	  a	  sputum	  sample	  for	  culture	  and	  speciation	  of	  
Mycobacterium	  tuberculosis,	  were	  encouraged	  to	  go	  for	  voluntary	  counselling	  and	  testing	  of	  
HIV	  status	  (HCT),	  and	  by	  means	  of	  questionnaire	  were	  asked	  about	  their	  TB	  symptoms,
smoking	  history,	  diabetic	  status	  and	  HIV	  status. Blood	  glucose	  measurements	  were	  obtained	  
by	  means	  of	  finger-­‐prick	  testing	  to	  determine	  the	  prevalence	  of	  hyperglycaemia.	  Written	  
consent	  was	  also	  obtained	  for	  analysis	  of	  data	  collected.	  
Study	  Population	  and	  Sampling	  
The	  study	  population	  comprises	  of	  South	  African	  and	  Zambian	  ZAMSTAR	  TB	  Prevalence	  
survey	  respondents.	  This	  survey	  was	  conducted	  as	  a	  means	  of	  determining	  TB,	  HIV,	  diabetes	  
and	  smoking	  prevalences	  in	  8	  communities	  in	  the	  Western	  Cape,	  South	  Africa	  and	  16	  in	  
Zambia.	  	  
These	  ZAMSTAR	  communities	  had	  in	  the	  preceding	  three	  years	  been	  randomised	  to	  receive	  











prevalences	  in	  the	  community.	  Communities	  were	  defined	  as	  a	  population	  served	  by	  one	  
primary	  health	  care	  diagnostic	  centre.	  Communities	  were	  then	  stratified	  into	  similar	  groups	  
based	  on	  country	  and	  or	  urban	  population	  and	  then	  randomly	  allocated	  to	  one	  of	  the	  four	  
intervention	  arms	  of	  the	  study.(10)
The	  ZAMSTAR	  prevalence	  survey	  occurred	  at	  the	  end	  of	  the	  intervention	  periods	  within	  each	  
of	  the	  communities	  during	  2010.	  	  
The	  prevalence	  survey	  was	  conducted	  in	  each	  of	  the	  communities	  in	  which	  the	  ZAMSTAR	  
interventions	  occurred.	  	  These	  communities	  were	  subdivided	  into	  Standard	  Enumeration	  
Areas	  (SEA)	  using	  national	  census	  maps	  and	  Google	  Earth.	  	  Each	  SEA	  within	  a	  sampling	  area	  
of	  that	  community	  was	  given	  a	  sampling	  number	  and	  the	  order	  of	  selection	  determined	  by	  
random	  number	  generation.	  Starting	  with	  the	  first	  randomly	  selected	  SEA	  all	  households	  
within	  that	  SEA	  were	  visited	  and	  eligible	  adults	  were	  enumerated	  and	  interviewed	  with	  
consent.	  In	  total	  64	  463	  participants	  were	  enrolled	  across	  the	  24	  study	  sites	  in	  Western	  
Cape,	  South	  Africa	  and	  in	  Zambia.	  	  
Sample	  Size	  
The	  ZAMSTAR	  prevalence	  survey	  was	  not	  designed	  to	  answer	  our	  question.	  Thus	  the	  sample	  
size	  is	  fixed	  and	  was	  the	  result	  of	  the	  ZAMSTAR	  protocol	  and	  study	  design.	  The	  ZAMSTAR	  
prevalence	  survey	  assumed	  a	  TB prevalence	  in	  the	  control	  arm	  of	  1%,	  and	  was	  powered	  to	  
detect	  a	  30%	  reduction	  in	  prevalence	  of	  tuberculosis	  from	  each	  intervention	  individually,
and	  a	  further	  30%	  reduction	  when	  both	  interventions	  were	  combined.	  (10)
Data	  Collection	  methods	  ZAMSTAR	  prevalence	  survey	  
Questionnaire:	  
Trained	  research	  assistants	  recruited	  participants	  door-­‐to-­‐door	  in	  the	  community	  and	  
administered	  a	  questionnaire.	  Questions	  were	  read	  to	  participants	  and	  recorded	  using	  
handheld	  electronic	  devices	  which	  obtained	  information	  regarding	  demographics,	  TB	  status,	  












The	  sputum	  samples	  were	  collected	  from	  these	  participants	  and	  were	  transported	  to	  the	  
ZAMSTAR	  laboratories	  where	  they	  were	  inoculated	  for	  culture,	  subjected	  to	  TBcID	  and	  HAIN	  
assays	  and	  then	  further	  speciated	  using	  16s	  DNA	  sequencing	  for	  Mycobacterium	  tuberculosis	  
complex.	  A	  positive	  16s	  result	  for	  Mycobacterium	  tuberculosis	  complex	  was	  considered	  the	  
definition	  of	  a	  positive	  TB	  case.	  
HIV	  Blood	  samples:	  
Participants	  who	  consented	  to	  HCT	  had their	  HIV	  tests	  performed	  either	  in	  the	  house	  by	  
trained	  study	  staff	  or	  were	  taken	  to	  a	  mobile	  testing	  tent	  in	  the	  community.	  	  Individuals	  who	  
tested	  HIV-­‐positive	  on	  Abbot	  Determine	  HIV	  1/2	  test	  had	  a	  confirmatory	  test	  using	  Unigold.	  
If	  the	  2	  tests	  were	  discordant,	  a	  tie-­‐breaker	  was	  done	  in	  the	  community	  health	  facility.
Blood	  Glucose	  samples:	  
Participants’	  blood	  glucose	  measurements	  were	  recorded	  by	  means	  of	  finger-­‐prick	  blood	  
glucose	  testing	  performed	  in	  the	  homes	  or	  in	  mobile	  HCT	  tents	  using	  a	  glucometer. Those	  
with	  a	  single	  random	  blood	  glucose	  level	  of	  more	  than	  11.1mmol/L	  were	  referred	  to	  the	  
local	  clinics	  for	  further	  diabetic	  work-­‐up	  and	  management.
All	  data	  were	  entered	  using	  a	  Standard	  Query	  Language	  (SQL)	  database.
Extraction	  of	  Data	  for	  this	  study	  
All	  enrolled	  ZAMSTAR	  prevalence	  survey	  participants	  	  will	  have	  their	  data	  analysed.	  The	  data	  
sources	  will	  be	  extracted	  from	  a	  locked	  database	  from	  the	  ZAMSTAR	  survey	  and	  no	  names	  
will	  be	  utilised.	  












• The	  individual	  participant’s	  responses	  to	  TB	  symptom	  and	  HIV,	  diabetes,	  and	  smoking	  
questions	  asked	  using	  the	  ZAMSTAR	  prevalence	  survey	  questionnaire.	  	  
• The	  ZAMSTAR	  laboratory	  diagnosis	  of	  M.TB	  from	  sputum	  culture	  and	  speciation.	  
• The	  HCT	  and	  blood	  sugar	  results.	  
.	  
5. SPECIFIC	  VARIABLES	  AND	  DEFINITIONS	  	  
Risk	  factors	  
	  
HIV	  status:	  HIV	  positive	  participants	  were	  defined	  as	  those	  with	  a	  confirmed	  positive	  HIV	  
rapid	  test	  result,	  supplemented	  by	  the	  self-­‐reporting	  of	  HIV	  status	  for	  individuals	  who	  did	  
not	  give	  a	  blood	  sample	  for	  HIV	  testing.	  	  
Smoking:	  “Current	  smokers”	  at	  the	  time	  of	  the	  survey	  were	  determined	  via	  questionnaire.	  
Participants	  who	  answered	  “yes”	  to	  the	  question	  “have	  you	  ever	  smoked”	  and	  also	  
answered	  that	  they	  had	  not	  stopped	  smoking	  were	  defined	  as	  current	  smokers.	  	  
Hyperglycaemia:	  Participants	  were	  defined	  as	  hyperglycaemic	  if	  a	  random	  capillary	  blood	  
glucose	  was	  >11.1mmol/L	  and/or	  if	  they	  self-­‐reported	  that	  they	  were	  diabetic	  	  
Symptom	  variables	  	  
	  
These	  were	  obtained	  through	  answering	  yes/no	  questions	  regarding	  the	  experience	  of	  the	  
following	  symptoms:	  
1. Cough	  
2. Chest	  pains	  
3. Fever	  
4. Night	  sweats	  
5. Unintentional	  loss	  of	  weight	  











Data	  Analysis	  	  
All	  ZAMSTAR	  TB	  prevalence	  survey	  respondents	  will	  be	  specifically	  categorised	  into	  those	  
with	  or	  without	  co-­‐morbidities,	  those	  with	  or	  without	  bacteriologically	  confirmed	  TB,	  and	  
those	  who	  did	  or	  did	  not	  report	  TB	  symptoms.	  A	  univariate	  and	  multivariate	  statistical	  
analysis	  will	  be	  undertaken	  using	  the	  statistical	  analysis	  programme	  STATA	  12	  for	  Windows	  
(StataCorp	  LP,	  College	  Station,	  TX,	  USA).	  The	  measure	  of	  association	  used	  will	  be	  the	  odds	  
ratio	  and	  corresponding	  95%	  confidence	  interval.	  Odds	  ratios	  will	  be	  calculated	  overall	  for	  
any	  co-­‐morbidities	  by	  any	  symptoms	  reported,	  and	  for	  individual	  co-­‐morbidities	  by	  
individual	  symptom.	  
6. ETHICAL	  CONSIDERATIONS
Ethics	  approval	  for	  the	  ZAMSTAR	  prevalence	  survey	  was	  obtained	  from	  the	  London	  School	  of	  
Hygiene	  and	  Tropical	  Medicine	  Ethics	  committee,	  The	  University	  of	  Zambia	  Ethics	  
Department	  and	  Stellenbosch	  University’s	  Ethics	  Department.	  Ethics	  approval	  for	  this	  
specific	  study	  has	  been	  approved	  by	  the	  International	  Union Against	  Tuberculosis	  and	  Lung	  
Disease	  Ethics	  Advisory	  Group.	  The	  database	  is	  locked	  and	  unique	  barcode	  identifiers	  were	  
used	  to	  ensure	  anonymity	  and	  protect	  participant	  information.	  No	  names	  will	  be	  revealed	  
during	  the	  extraction	  of	  data	  for	  this	  study.	  
7. STRENGTHS	  AND LIMITATIONS
Strengths	  
The	  data	  required	  to	  answer	  the	  study	  question	  has	  been	  collected	  and	  cleaned,	  and	  is	  ready	  
for	  analysis.	  The	  number	  of	  participants	  recruited	  was	  large,	  resulting	  in	  a	  wealth	  of	  
individual	  data	  which	  adds	  to	  the	  power	  of	  the	  analysis.	  A	  major	  strength	  of	  the	  study	  is	  that	  
it	  provides	  a	  large	  sample	  of	  TB	  cases	  confirmed	  through	  16SDNA	  sequencing,	  detected	  in	  
the	  community	  outside	  of	  the	  health	  system.	  Additionally,	  these	  cases	  have	  corresponding	  














The	  ZAMSTAR	  prevalence	  survey	  was	  not	  specifically	  designed	  for	  this	  study	  question	  and	  
the	  complexity	  of	  the	  study,	  along	  with	  the	  very	  large	  number	  of	  participants	  may	  result	  in	  
missing	  data	  which	  could	  ultimately	  affect	  the	  power	  of	  the	  study.	  Furthermore,	  we	  are	  
limited	  in	  the	  conclusion	  we	  can	  make	  regarding	  hyperglycaemia	  as	  the	  results	  are	  based	  on	  
a	  single	  and	  random	  blood	  sugar	  reading.	  
	  
8. IMPACT	  AND	  DISSEMINATION	  
These	  results	  would	  add	  to	  the	  knowledge	  of	  symptom-­‐screening	  use	  for	  TB	  suspects	  in	  
community	  surveys.	  The	  study	  has	  the	  potential	  to	  add	  insight	  into	  the	  reporting	  of	  
symptoms	  among	  TB	  cases	  with	  co-­‐morbidities	  and	  may	  inform	  symptom-­‐based	  algorithms	  
for	  any	  TB	  suspect	  cases	  during	  active	  case-­‐finding	  in	  communities.	  We	  aim	  to	  disseminate	  
any	  knowledge	  generated	  from	  this	  study	  through	  scientific	  manuscript	  publication.	  
9. PROJECT	  MANAGEMENT	  
	  
Data	  has	  already	  been	  collected	  and	  analysis	  will	  occur	  once	  approval	  has	  been	  granted	  by	  
the	  Human	  Research	  Ethics	  Committee	  of	  the	  Health	  Sciences	  Faculty	  at	  the	  University	  of	  
Cape	  Town.	  
10. BUDGET	  	  
No	  budget	  is	  requested.	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1. ZAMSTAR	  CONSENT	  FORM
2. ZAMSTAR	  TB	  PREVALENCE	  SURVEY	  QUESTIONNAIRE
3. ZAMSTAR	  SAMPLING	  FRAME
Appendix	  1:	  ZAMSTAR	  Consent	  Form	  
INFORMED	  CONSENT	  FORM	  FOR	  TB	  PREVALENCE	  SURVEY	  (PERSONS	  AGED	  18	  YEARS	  AND	  
OLDER)
Declaration	  by	  participant	  
I	  confirm	  that	  I	  have	  read	  the	  information	  sheet,	  and	  that	  the	  information	  and	  procedures	  involved	  in
my taking part in this survey have been explained to me.
1. I	  confirm	  that	  I	  have	  had	  the	  opportunity	  to	  ask	  questions	  about	  the survey and that I am
satisfied with the answers	  provided.
2. I	  have	  been	  given	  time	  and	  opportunity	  to	  read	  the	  information	  carefully,	  to	  discuss	  it	  with
others and	  to	  decide whether or not to	  take part in	  this survey.
3. I	  understand	  that	  if	  I	  am	  diagnosed	  with	  TB, I will be informed	  and	  that I will be referred	  for
treatment	  to my local TB clinic.
4. I	  understand	  that	  if	  the	  TB	  test	  is	  positive,	  the	  clinic	  will	  be	  informed.	  That	  the	  study	  team
will	  look	  in	  the	  TB	  treatment	  register	  to	  see	  whether	  I	  have	  started	  and	  completed
treatment.
5. I	  understand	  that	  if	  the	  TB	  test	  is	  positive,	  there	  will	  be	  further	  tests	  to	  determine	  whether













6. I	  understand	  that	  the	  TB	  culture	  will	  be	  kept	  in	  a	  sample	  bank	  with	  only	  a	  bar	  code	  on	  (not
my	  name)	  and	  that	  this	  sample	  can	  be	  used	  in	  future	  for	  further	  tests	  on	  the	  TB	  organisms
7. I	  understand	  that	  I	  may	  choose	  to	  get	  the	  result	  of	  my	  HIV	  test	  if	  I	  want	  the	  result
8. I	  understand	  that	  I	  will	  have	  pre-­‐test	  and	  post-­‐test	  counselling	  for	  HIV	  and	  that	  I	  will	  be
referred	  to	  the	  clinic	  for	  care	  should	  the	  test	  be	  positive.
9. I	  understand	  that	  I	  may	  refuse	  the	  HIV	  test	  or	  that	  I	  may	  choose	  to	  have	  the	  test	  done,	  but
not	  receive	  the	  results
10. I	  understand	  that	  the	  results	  of	  the	  blood	  sugar	  test	  will	  be	  given	  to	  me	  and	  that	  I	  will	  be
referred	  to	  the	  clinic	  for	  appropriate	  care	  if	  my	  blood	  sugar	  is	  too	  high.
11. I	  understand	  that	  I	  will	  be	  given	  information	  about	  TB,	  HIV,	  diabetes, use	  of tobacco, and use	  
of alcohol.
12. I	  understand	  that	  refusal	  to	  have	  HIV	  and	  Blood	  sugar	  tests	  done	  does	  not	  preclude	  me	  from
participating in	  this study as long as I submit a respiratory sample for evaluation.
13. I	  understand	  that	  the	  research	  team	  can	  access	  my	  results	  from	  the	  VCT	  register	  if	  I
previously	  tested	  at	  their	  outreach	  centre.
14. I	  understand	  that	  the	  researchers	  will	  keep	  all	  my	  personal	  information	  confidential.
15. I	  understand	  that	  I	  will	  not	  get	  any	  financial	  reward	  for	  taking	  part	  in	  this	  survey.
16. I	  understand	  that	  the	  results	  of	  this	  study	  will	  be	  published	  in	  scientific	  journals	  but	  that	  my
name will never be used.
17. I	  understand	  that	  I	  may	  in	  future	  be	  requested	  to	  participate	  in	  follow-­‐up	  studies	  but	  that	  I
may	  decline	  at	  a	  later	  stage	  to	  take	  part	  in	  future	  studies.
18. I	  agree	  to	  take	  part	  in	  the	  survey.
By	  signing	  below,	  I	  (Please	  Print)	  	  
(First	  Name)___________________________(Surname)	  ________________________________	  











Signed	  at	  (place)	  ......................…........……………..	  on	  (date	  (dd/mm/yyyy))	  ____________________	  
 .............................................................................  ..........................................................................  
Signature	  of	  participant	   Signature	  of	  witness	  if	  needed	  
Declaration	  by	  Research	  Assistant	  
I	  (First	  Name)___________________________(Surname)	  ________________________________	  
declare	  that:	  
• I	  explained	  the	  information	  in	  this	  document	  to	  …………………………………..	  
• I	  encouraged	  him/her	  to	  ask	  questions	  and	  took	  adequate	  time	  to	  answer	  them.
• I	   am satisfied that he/she adequately understands all	   aspects of the research, as
discussed	  above
• I	  did/did not use a interpreter. (If an interpreter is used then the interpreter must sign
the declaration below.
Signed at (place)	  ......................…........…………….. on (date)	  …………....………………….
.............................................................................  ..........................................................................  
Signature	  of	  Research Assistant Signature	  of	  witness	  if	  needed	  
Declaration	  by	  interpreter	  
I	  (First	  Name)___________________________(Surname)	  ________________________________	  
declare	  that:	  
I	  assisted	  the	  investigator	  (name)	  ……………………………………….	  to	  explain	  the	  information	  in	  this	  
document	  
to	  (name	  of	  participant)	  ……………..……………………………..	  using	  the	  language	  medium	  of	  
Afrikaans/Xhosa.	  











• I	  conveyed	  a	  factually	  correct	  version	  of	  what	  was	  related	  to	  me.
• I	  am	  satisfied	  that	  the	  participant	  fully	  understands	  the	  content	  of	  this	  informed	  consent
document	  and	  has	  had	  all	  his/her	  question	  satisfactorily	  answered.
Signed	  at	  (place)	  ......................…........……………..	  on	  (date)	  …………....……………….	  
 .............................................................................  ..........................................................................  
Signature	  of	  interpreter	  .....................................	  Signature	  of	  witness	  if	  needed 
Appendix	  2:	  ZAMSTAR	  Prevalence	  Survey	  Questionnaire	  2010
SECTION 1
ALL QUESTIONS IN THIS SECTION MUST BE ANSWERED
HOUSEHOLD BARCODE
Q01_INC	   Interviewer’s	  code	  
Q02_DAT	   Date	  today	  
D	   D	   M	   M	   Y	   Y	   Y	   Y	  
Q03_SEN	   Serial	  Number	  











Q05_HOH	   Are	  you	  the	  Head	  of	  Household?	   No	   Yes	  
0	   1	  
Q06_SEX	   Sex	   M	   F	  
1	   2	  
Q07_AGE	   Age	  
Q08_MAR	   Married	  to	  
Q09_DIS	   Disability?	  
No	  Disability	   1	  
Sight(blind/	  severe	  visual	  impairment)	   2	  
Hearing	  (deaf/	  profoundly	  hard	  of	  	  hearing)	   3	  
Communication(speech	  impairment)	   4	  
Physical(needs	  wheelchair/	  crutches)	   5	  
Mental	  disability	   6	  
Q10_CON	   Consent	   No	   Yes	   Absent	   Excluded	  











ONLY	  CONTINUE	  IF	  CONSENT	  IS	  GIVEN	  
SECTION	  2	  –	  FILL	  THIS	  SECTION	  AND	  SUBSEQUENT	  SECTIONS	  IN	  ONLY	  IF	  PERSON	  HAS	  GIVEN	  
CONSENT	  	  
Q11_DOB	   Date	  of	  Birth	  (01/01/1800	  if	  unknown)	  
D	   D	   M	   M	   Y	   Y	   Y	   Y	  If	  not	  known,	  what	  was	  your	  age	  in	  
Q11_1_DOB	  years	  at	  your	  last	  birthday?	  
(999	  if	  unknown)	  
Q12_YLC	   How many years have you lived in this community?
Write down actual number, zero if less than one year)
Q13_RAC	   What is your race?
Select only one	  option Black	   1	  
Coloured	   2	  
Indian/Asian	   3	  
White	   4	  
Other	   5	  
Q14_COB	   What	  is	  your	  country	  of	  birth?	  












Q15_HZS	   Before	  this	  survey,	  have	  you	  heard	  of	  or	  been	  involved	  with	  
ZAMBART/ZAMSTAR	  (DTTC/	  ZAMSTAR	  for	  SA)	  
No	   Yes	  
0	   1	  
Q16_CMS	   	  What	  is	  your	  current	  marital	  Status?	  
If	  married,	  Divorced	  or	  widowed,	  continue,	  If	  never	  married	  go	  to	  Q18	  
Never	  married	   1	  
Currently	  married	  or	  living	  as	  married	   2	  
Divorced	  or	  Separated	   3	  
Widowed	   4	  
Q17_AFM	   	  Age	  at	  first	  marriage?	  (years)	  
Q18_MOY	   What has been your main
occupation	  during the past year?
Unemployed/working	  on	  own	  land	   1	  
Occasional/seasonal	  employment	   2	  
Employed	  (Formal	  employment	  or	  self-­‐
employed	  making	  money)	  
3	  
Unable	  	  to	  work	   4	  
Student	   5	  
Housewife/	  home-­‐maker	   6	  











Q19_CSH	   How	  would	  you	  classify	  your	  smoking	  habits?	  
Have	  never	  Smoked	   1	  
Daily	  Smoker	   2	  
Occasional	  smoker	   3	  
Ex-­‐Smoker	   4	  
Q20_CDH	   How	  would	  you	  classify	  your	  drinking	  habits?	  
Have	  never	  drunk	   1	  
Daily	  drinker	   2	  
Occasional	  drinker	   3	  
Ex-­‐drinker	   4	  
Q21_HEA	   What	  is	  the	  highest	  level	  of	  education	  you	  have	  
attained?	  	  	  
No	  Formal	  Education	   0	  
Grade	  1-­‐12(Indicate	  actual	  grade)Note	  Grade	  8-­‐12	  is	  also	  Form	  1	  –form	  5	  
College	   20	  
University	   30	  











If	  has	  attended	  school,	  continue,	  if	  No	  formal	  education	  go	  to	  Q23	  
Q22_YES	   When	  was	  the	  last	  year	  you	  were	  in	  enrolled	  
	  in	  School/College/University?	  Enter	  9999	  if	  year	  is	  not	  known	   Y	   Y	   Y	   Y	  
Q23_OCC	   Please	  state	  main	  occupation	  at	  
age	  15	  years?	  
Unemployed/	  working	  on	  own	  land	   1	  
Seasonal/Occasional	  employment	   2	  
Employed	  (formal	  employment	  or	  self	  employed	  
earning	  money)	  
3	  
Unable	  to	  work	   4	  
Student	   5	  
Housewife/home-­‐maker 6	  
Can’t remember 9	  
Q24_CTB	   Are you	  currently on	  TB	  treatment? Probe and	  be sure only conventional
treatment(on ATT)	  
No	   Yes	  
0	   1	  
(If	  yes	  continue,	  If	  No	  goto	  Q35)	  
























Pharmacy	   4	  
Private	  Doctor	   5	  
Traditional	  Healer	   6	  
Sputum	  collection	  point	   7	  
Q26_TCA	   Is	  TB	  treatment	  card	  available?	  (confirm	  by	  seeing	  the	  card)	   No	   Yes	  
If	  yes	  continue,	  If	  No	  go	  to	  Q31	   0	   1	  
Q27_DTS	   Date	  treatment	  started	  
D	   D	   M	   M	   Y	   Y	   Y	   Y	  
Q28_TTN	   TB treatment	  Number (from treatment	  
card)
Q29_CAT Category of TB	  as recorded on card?
Sputum	  	  smear	  Positive	   1	  
Sputum	  smear	  Negative	   2	  
Extrapulmonary	   3	  
Unknown/not	  recorded	   4	  
Q30_TTC	   TB	  treatment	  Centre(as	  written	  on	  card)	  












Q31_MST	   Which	  month	  did	  you	  start	  treatment	  
January	   1	  
February	   2	  
March	   3	  
April	   4	  
May	   5	  
June	   6	  
July	   7	  
August	   8	  
September	   9	  
October	   10	  
November	   11	  
December	   12	  
Unknown	   99	  
Q32_SPT Was	  the	  sputum	  smear	  positive	  for	  TB?	   No	   Yes	   Unk	  
0	   1	   9	  
Q33_RTF	   Where	  are	  you	  receiving	  your	  TB	  
treatment	  from?	  
Government/Community	  clinic	   1	  











Government	  Provincial/District	  hospital	   3	  
Pharmacy	   4	  
Private	  Doctor	   5	  
Q34_TTC	   TB	  treatment	  Centre	  
	  Previous	  TB	  treatment	  
Q35_TTB	   Have	  you	  ever	  been	  on	  TB	  treatment	  before?	   No	   Yes	   Unk	  
	  If	  yes	  continue,	  if	  no	  go	  to	  Q37	   0	   1	   9	  
Q36_HMT	   How	  many	  times?	  
Once	   1	  
Twice	   2	  
Three	  times	   3	  
More	  than	  three	  times	   4	  
Unknown	   9	  
Q37_CHC	   Do	  you	  currently	  have	  a	  cough?	   No	   Yes	  
If	  yes	  continue,	  if	  no	  go	  to	  Q41	   0	   1	  
I	  would	  like	  to	  ask	  about	  your	  current	  state	  of	  health	  











Q38_WBC How	  many	  weeks	  have	  you	  been	  coughing?	  Box	  
write	  actual	  number	  of	  weeks	  
Q39_CPS	   Do	  you	  currently	  produce	  sputum	   No	   Yes	  
0	   1	  
Q40_CCB	   Do	  you	  currently	  cough	  up	  blood?	   No	   Yes	  
0	   1	  
Q41_CAC	   Did	  you	  consult	  anybody	  for	  this	  cough?	   No	   Yes	  
If	  yes	  continue,	  if	  no	  go	  Q47	   0	   1	  
Q42_GHF	   Where	  did	  you	  go	  for	  help	  first?	  
Government /Community clinic 1	  
Private	  clinic/hospital 2	  
Government Provincial/ District hospital 3	  
Pharmacy 4	  
Private	  Doctor 5	  
Traditional healer 6	  
Sputum collection point (ZAMBART/ZAMSTAR/) 7	  
If	  1,	  2,	  3	  go	  to	  Q44	  …	  
Q43_GCP	   If	  pharmacy/private/tradition	  healer,	  did	  you	  ever	  go	  to	  a	  
government/community/sputum	  collection	  point	  
No	   Yes	  
0	   1	  











	  If	  yes	  continue,	  if	  no	  go	  to	  Q	  47 0	   1	  
Q45_DGS If	  yes,	  did	  you	  give	  sputum?	   No	   Yes	  
If	  yes	  continue,	  if	  no	  go	  to	  Q47	   0	   1	  
Q46_RES	   What	  was	  the	  result?	  
Negative for TB 0	  
Positive	  for TB 1	  
Unknown/can’t remember 9	  
Other	  symptoms	  
Q47_CCP	   Do	  you	  currently	  have	  chest	  pains?	   No	   Yes	  
0	   1	  
Q48_CHF	   Do you currently have fever? No	   Yes	  
0	   1	  
Q49_DNS	   Do you currently have drenching night sweats? No	   Yes	  
0	   1	  
Q50_LWU	   In	  the	  last	  month	  have	  you	  lost	  weight	  unintentionally?	   No	   Yes	  
0	   1	  
Q51_DBB	   Do	  you	  currently	  have	  difficulty	  breathing	  or	  shortness	  of	  breath?	   No	   Yes	  
0	   1	  











Q52_THD	   Have	  you	  ever	  been	  told	  you	  have	  diabetes	   No	   Yes	  
If	  Yes	  continue,	  if	  No	  go	  to	  Q55	   0	   1	  
Q53_CAT	   If	  yes,	  are	  you	  currently	  on	  any	  treatment	  for	  diabetes?	   No	   Yes	  
If	  yes	  continue	  If	  no	  go	  to	  Q55	   0	   1	  
Q54_TON	   What	  treatment	  are	  you	  on?	  
Dietary	  only	   1	  
Tablets	   2	  
Insulin	  injections	   3	  
Q55_KHS	   Do	  you	  know	  your	  HIV	  status?	   No	   Yes	  
0	   1	  
Q56_DHS	   Are you	  willing to	  disclose your HIV status? No	   Yes	  
If	  yes	  continue,	  if	  not	  willing	  to	  discuss	  go	  to	  Q60 0	   1	  
Q57_HIV	   What	  is	  your	  HIV	  status?	  
Negative	   0	  
Positive	   1	  
	  If	  HIV	  status	  is	  Positive,	  continue,	  if	  no	  go	  to	  Q54	  
Q58_ART	   Are	  	  you	  on	  Antiretroviral	  treatment(	  ART)	   No	   Yes	  











Q59_LAR	   How	  long	  have	  you	  been	  on	  ART?	  	  Write	  down	  actual	  
number	  of	  months	  
Q60_CIR	   Are	  you	  circumcised?	   No	   Yes	   unk	  
If	  yes	  continue,	  if	  no	  go	  to	  Q62	   0	   1	   9	  
Q61_WCI	   When	  were	  you	  circumcised?	  
Infant/Child	   1	  
Adolescent	   2	  
Adult 3	  
Unknown/Can’t remember 9	  
Q62_WEI	   Weight?	  Record	  weight	  in	  Kilograms	  
If	  not	  done,	  write	  999.	  9	  
Q63_HEI	   Height? Record height in centimeters
If	  not	  done,	  write	  999.9
Q64_ABC	   Abdominal	  Circumference?	  Record	  in	  centimeters	  












Q65_BLG	   Blood	  Glucose.	   Write	  actual	  Results	  below	  
Q66_HIV_DET	   HIV	  Test	  result	  (Determine).	  
HIV	  result	  Negative	   0	  
HIV	  result	  Positive	   1	  
HIV	  test	  	  not	  done	   9	  
Q67_HIV_UNI If	  positive,	  confirmatory	  HIV	  Test	  result
(UniGold).	  
HIV	  result	  Negative	   0	  
HIV	  result	  Positive	   1	  
HIV	  test	  	  not	  done	   9	  
Q68_HSP	   HIV	  test	  results	  given	  to	  study	  participant?	   No	   Yes	  




d	   d	   m	   m	   y	   Y	   y	   y	  













Appendix	  3:	  ZAMSTAR	  Sampling	  SOP	  
	  
	  
APPENDIX	  3:	  Sampling	  and	  Enumeration	  SOP	  
Aim:	  To	  sample	  5000	  consenting	  adults	  who	  are	  representative	  of	  the	  community	  
The	  ZAMSTAR	  community	  is	  defined	  as	  a	  catchment	  area	  of	  one	  or	  more	  TB	  clinics	  with	  a	  minimum	  
number	  of	  25,	  000	  people	  in	  that	  area.	  The	  Intervention	  area	  is	  defined	  as	  the	  area	  within	  the	  
ZAMSTAR	  community	  where	  interventions	  have	  been	  implemented.	  	  The	  sample	  area	  is	  defined	  as	  
the	  whole	  intervention	  area	  or	  a	  part	  of	  the	  intervention	  area	  where	  it	  is	  expected	  that	  the	  
interventions	  are	  most	  effective.	  
Step	  1:	  National	  census	  maps	  of	  the	  ZAMSTAR	  community	  and	  Google	  earth	  will	  be	  used	  to	  generate	  
electronic	  maps.	  Standard	  Enumeration	  Areas	  (SEAs)	  will	  be	  marked	  on	  these	  maps.	  
Step	  1a:	  In	  consultation	  with	  the	  team	  leaders,	  the	  intervention	  area	  will	  be	  drawn	  onto	  electronic	  
maps.	  The	  intervention	  area	  is	  the	  area	  where	  the	  interventions	  have	  actually	  been	  implemented	  
and	  may	  differ	  (slightly)	  from	  the	  original	  planned	  area.	  
Step	  2:	  	  Sampling	  area	  rules	  and	  definition	  
• Subdivide	  the	  SEAs	  within	  the	  intervention	  area	  into	  SEAs	  with	  <1000	  people.	  
• Boundaries	  of	  selected	  SEA	  must	  be	  completely	  within	  the	  intervention	  area.	  
• Start	  circling	  clockwise	  around	  the	  clinic,	  select	  the	  enumeration	  areas	  and	  select	  the	  SEA’s	  
until;	  
o The	  intervention	  area	  is	  included	  
OR	  
code	   	  
Interviewer	  	   	   	   	   	   	   	   	   	   	   	  
Field	  manager	  	   	   	   	   	   	   	   	   	   	   	  
1st	  data	  entry	   	   	   	   	   	   	   	   	   	   	  











o 25,000	  people	  are	  selected.
• If	  the	  community	  has	  2	  clinics,	  start	  circling	  around	  each	  clinic,	  select	  the	  enumeration	  areas
and	  select	  the	  SEA	  until;
o The	  whole	  intervention	  area	  is	  included
OR	  
o 12,500	  people	  are	  selected.
Step	  3:	  Each	  SEA	  within	  a	  sampling	  area	  will	  be	  given	  a	  sequential	  number	  and	  the	  order	  of	  selection	  
will	  be	  determined	  by	  generating	  these	  numbers	  into	  a	  random	  order.	  	  
Step	  4:	  Starting	  with	  the	  first	  randomly	  selected	  SEA-­‐	  all	  households	  in	  the	  SEA	  will	  be	  visited	  and	  all	  
adults	  who	  slept	  in	  the	  household	  in	  the	  last	  24	  hours	  will	  be	  enumerated	  and	  interviewed	  with	  
consent.	  	  
Step 5: On completion of an entire SEA the next SEA will be visited and the same procedure
completed. This	  will continue until a sample of 5000 adults	  have consented and been recruited. The
SEA containing the	  5000th adult must be	  completed.
Step 6:Where an adult is enumerated but not present at the time of the survey 2 further visits to the
household	  will be made. These visits should	  be timed	  such	  that there is maximum chance of finding
the absent	  adult	  and this timing will depend on the individual circumstances of	  the adult. These visits
should be recorded in the diary of the research team.
Step 7:Where an adult cannot be found after 2 visits or in the case of non-­‐consent by an adult the	  
management form	  must be completed to indicate this.
Step 8: The first section of the questionnaire must be completed	  for every adult who	  is enumerated.
In	  the	  case	  of	  the	  adult	  not	  being	  found	  or	  non-­‐consent, only	  the first section of the questionnaire
will be completed. The information given by the other household members regarding age and sex











Part	  B:	  Structured	  literature	  review
a) Objectives	  of	  Literature	  Review
• To	  introduce	  the	  global	  issues	  of	  tuberculosis	  (TB)	  detection	  in	  communities	  using
symptoms	  screening.
• To	  examine	  the	  relationship	  of	  tuberculosis	  with the high	  risk groups	  of	  people	  living	  
with	  the	  human	  immunodeficiency	  virus	  (HIV),	  those	  with	  diabetes	  mellitus (DM),	  
and	  cigarette	  smokers.
• To	  discuss	  the	  benefits	  of	  using	  a	  symptom-­‐screening	  tool	  in	  high	  risk	  groups	  to	  
detect	  TB	  through	  active	  case-­‐finding.
• To	  identify	  gaps	  in	  the	  literature.
b) Literature	  search	  strategy
Internet	  search	  engine	  Google	  Scholar,	  the	  electronic	  database	  Pubmed,	  and	  the	  electronic	  
databases	  of	  Stellenbosch	  University	  and	  the	  University	  of	  Cape	  Town	  were	  utilised.	  
Keywords	  inputted	  were:	  symptom	  screening;	  tuberculosis;	  active	  case-­‐finding; TB	  screening
in	  high	  risk	  groups;	  TB	  and	  non-­‐communicable	  diseases;	  TB	  and	  smoking;	  TB	  and	  diabetes;	  
TB	  and	  HIV;	  co-­‐morbidity	  effects	  on	  TB	  symptom	  reporting;	  TB	  symptom	  reporting	  
differences	  and	  influences.	  
c) Quality	  and	  relevance	  criteria	  by	  which	  studies	  were	  included
Only	  scientific	  manuscripts	  published	  in	  peer-­‐reviewed	  journals	  were	  included.	  All	  articles	  
were	  published	  between	  1998	  and	  2012.	  The	  reference	  lists	  of	  these	  articles	  were	  also	  
reviewed	  for	  additional	  studies.	  	  TB	  experts	  were	  consulted	  to	  suggest	  appropriate	  articles	  


















Current	   and	  previous	   strategies	   to	   control	   the	   global	   tuberculosis	   (TB)	   epidemic	   have	  had	  
minimal	   success.	   Due	   to	   the	   characteristics	   of	   infection,	   the	   slow-­‐growing	   nature	   of	   the	  
bacillus	   and	   the	   long	   delay	   between	   infection	   and	   manifestation	   of	   TB	   symptoms,	   the	  
infectious	  pool	   in	   the	  community	   is	   large.	  Passive	  case-­‐finding	  at	  health	   facilities	  has	  been	  
the	   mainstay	   of	   detection,	   but	   current	   strategies	   are	   moving	   towards	   active	   case-­‐finding	  
initiated	  by	  the	  provider	  in	  high	  burden	  areas	  and	  in	  high	  risk	  groups.	  	  TB	  symptom	  screening	  
questionnaires	  are	  the	  most	  practical	  tool	  to	  utilise	  in	  poor	  high	  burden	  areas,	  but	  unlike	  for	  
the	   high	   risk	   group	   of	   people	   living	   with	   HIV,	   there	   is	   a	   paucity	   of	   evidence	   surrounding	  
adaptation	  of	  symptom	  screening	  tools	   in	  other	  high	  risk	  groups	  for	  TB	  such	  as	  those	  with	  
diabetes	  mellitus	  or	   those	  who	  smoke	  cigarettes.	   	  This	   literature	   review	  aims	   to	   introduce	  
the	   scope	  of	   the	  global	  TB	  problem,	   the	   interplay	  between	  TB	  and	   the	  high	   risk	  groups	  of	  
HIV,	   those	   with	   diabetes	   mellitus	   and	   smoking,	   and	   how	   symptoms	   are	   manifested	  





Tuberculosis	  (TB)	  is	  an	  infectious	  disease	  caused	  primarily	  by	  the	  bacillus	  Mycobacterium	  
tuberculosis,	  but	  can	  also	  be	  caused	  by	  Mycobacterium	  bovis	  or	  Mycobacterium	  Africanum.	  
The	  mycobacterium	  bacillus	  is	  propagated	  through	  air-­‐borne	  spread	  and	  is	  inhaled	  by	  the	  
host	  after	  coming	  into	  contact	  with	  an	  individual	  with	  active	  disease.(1)	  Thus	  the	  site	  of	  
pathology	  is	  primarily	  the	  lungs,	  with	  respiratory	  disease	  characterised	  by	  pleural	  effusions,	  
broncho-­‐penumonic	  processes,	  hilar	  lymphadenopathy	  and	  cavitation.(2)	  It	  can	  also	  be	  
ingested	  through	  contaminated	  food	  sources,	  causing	  intestinal	  pathology.	  (1,3)Primary	  











with	  latent	  TB	  have	  a	  10%	  lifetime	  risk	  of	  developing	  active	  TB	  but	  high	  risk	  groups	  such	  as	  
persons	  infected	  with	  the	  human	  immunodeficiency	  virus	  (HIV),	  those	  with	  diabetes	  
mellitus,	  or	  those	  who	  smoke	  cigarettes	  are	  at	  much	  higher	  risk	  of	  developing	  active	  disease	  
after	  infection.	  (4)	  	  	  Post-­‐primary	  pulmonary	  tuberculosis	  symptoms	  manifest	  gradually,	  with	  
the	  onset	  of	  symptoms	  taking	  many	  weeks	  hence	  a	  delay	  in	  the	  time	  between	  infection	  and	  
manifestation	  of	  symptoms,	  and	  seeking	  help	  at	  health	  facilities.(5)	  The	  symptom	  complex	  
most	  commonly	  complained	  of	  is	  a	  combination	  of	  a	  cough	  for	  longer	  than	  two	  weeks,	  
haemoptysis,	  night	  sweats,	  fever,	  loss	  of	  weight,	  shortness	  of	  breath	  and	  pleuritic	  chest	  pain.	  
(5) When	  TB	  causes	  disease	  in	  other	  organ	  systems,	  symptoms	  presented	  are	  appropriate	  to	  
the	  system	  involved.(2) TB	  is	  treated	  with	  a	  combination	  of	  oral and	  injectable	  
chemotherapeutic	  agents.	  Some	  mycobacteria	  are	  resistant	  to	  one	  or	  more	  of	  the	  first	  line	  
chemotherapeutic	  regimens,	  and	  the	  patients	  will	  then	  be	  infected	  with	  what	  is	  known	  as	  
multi-­‐drug	  resistant	  TB	  (MDR-­‐TB)	  or	  extremely	  drug-­‐resistant	  TB	  (XDR-­‐TB)	  and	  require	  
specialised	  treatment	  regimens.(3) TB	  is	  curable,	  however	  up	  to	  66%	  of	  individuals	  with	  TB	  
will	  die	  without	  proper	  treatment.	  (4)
Global tuberculosis Epidemiology
Although	  curable,	  TB	  remains	  a	  serious	  global	  threat	  to	  public	  health.	  (6) It	  is	  estimated	  that	  
approximately	  one	  in	  every	  three	  people	  globally	  is	  infected	  with	  latent	  TB.(7) It	  is	  ranked	  as	  
the	  second	  largest	  cause	  of	  death	  by	  infectious	  disease,	  HIV	  being	  the	  first.	  (8) In	  2011,	  8.7	  
million	  TB	  cases	  were	  reported	  world-­‐wide,	  with	  1.4	  million	  deaths	  directly	  attributable	  to	  
TB.	  	  It	  occurs	  in	  every	  country	  in	  the	  world,	  with	  the	  highest	  burden	  borne	  by	  developing	  
countries	  in	  the	  regions	  of	  Asia	  and	  Africa.	  (9) This	  is	  intimately	  linked	  with	  levels	  of	  poverty.	  	  
Overcrowding,	  poor	  living	  conditions,	  malnutrition	  and	  individual	  access	  to	  health	  facilities	  
are	  considered	  major	  social	  causes	  of	  tuberculosis,	  and	  imperative	  to	  tackle	  in	  order	  to	  stop	  
transmission.(10) According	  to the	  Global	  Tuberculosis	  Report	  2012,	  South-­‐East	  Asia	  and	  the	  
Western	  pacific	  regions	  account	  for	  60%	  of	  cases,	  with	  24%	  of	  cases	  in	  the	  Africa	  region.	  The	  
Africa	  region	  also	  has	  the	  highest	  death	  rates	  per	  capita	  from	  TB.	  (9) Global	  awareness	  of	  
the	  scope	  of	  morbidity	  and	  mortality	  caused	  by	  TB	  resulted	  in	  The	  United	  Nations	  including	  
the	  target	  of	  halting	  and	  reversing	  the	  global	  TB	  epidemic	  by	  2015	  in	  its	  Millenium	  











since	  1990	  TB	  mortality	  has	  declined	  by	  41%.	  But	  these	  overall	  achievements	  overshadow	  
the	  slow	  progress	  made	  in	  the	  African	  Region,	  which	  is	  not	  on	  target	  to	  achieve	  the	  MDG	  for	  
tuberculosis	  by	  2015.	  Furthermore	  Africa	  hosts	  almost	  80%	  of	  the	  global	  total	  of	  TB	  cases	  
who	  also	  have	  HIV.(9)	  	  
Tuberculosis	  epidemiology	  in	  high	  risk	  groups	  of	  people	  infected	  with	  the	  
human	  immunodeficiency	  virus,	  those	  with	  diabetes	  mellitus,	  and	  smokers	  
The	  number	  one	  risk	  factor	  for	  developing	  TB	  in	  both	  those	  with	  latent	  and	  new	  TB	  infection
is	  infection	  with	  HIV.	  TB	  is	  also	  the	  number	  one	  cause	  of	  death	  in	  persons	  with	  HIV,	  and	  
approximately	  one	  in	  four	  AIDS-­‐related	  deaths	  worldwide	  can	  	  be	  attributed	  to	  TB.(12)
People	  living	  with	  HIV,	  have	  a	  far	  greater	  risk	  of	  developing	  active	  TB	  than	  those	  without	  
HIV.	  	  The	  figures	  estimated	  by	  the	  World	  Health	  Organisation	  (WHO)	  show	  that	  people	  living	  
with	  HIV are	  at	  20	  to	  37	  times	  greater	  risk	  of	  getting	  TB,	  and	  of	  dying	  of	  TB.	  (7,12)	  This	  is	  due
to	  the	  fact	  that	  HIV	  hinders	  the	  body’s	  cellular	  immune	  system,	  thus	  it	  both	  increases	  the	  
chance	  of	  reactivating	  latent	  TB,	  and	  causes	  rapid	  progression	  of	  disease	  after	  infection	  or	  
reinfection.	  (13)Furthermore,	  the	  African	  region	  had	  the	  greatest	  proportion	  globally	  of	  
reported	  HIV-­‐positive	  TB	  cases	  at	  79%.(9)
Beside	  the	  additional	  threat	  of	  HIV,	  the	  increasing	  prevalence	  of	  non-­‐communicable	  
diseases,	  such	  as	  diabetes	  mellitus	  and	  smoking-­‐related	  conditions,	  provides	  the	  next	  wave	  
of	  high	  risk	  groups	  to	  target	  for	  TB	  control.(14).	  In	  places	  where	  HIV	  prevalence	  is	  low,	  non-­‐
communicable	  diseases	  such	  as	  and	  smoking,	  may	  contribute	  more	  to	  the	  development	  of	  
active	  TB	  than	  HIV.(14)
Diabetes	  mellitus	  and	  the	  association	  with	  TB	  is	  a	  link	  that	  has	  been	  recognised	  since	  ancient	  
times,	  and	  one	  that	  is	  backed	  up	  by	  strong	  scientific	  evidence.	  The	  rapid	  escalation	  of	  
diabetes	  mellitus	  globally	  has	  been	  said	  to	  be	  as	  great	  a	  threat	  to	  global	  tuberculosis	  control	  
in	  some	  areas	  as	  the	  rise	  of	  HIV.	  	  (15)	  	  The	  global	  prevalence	  of	  diabetes	  mellitus	  is	  expected	  
to	  more	  than	  double	  by	  2030	  with	  7	  out	  of	  the	  10	  countries	  with	  expected	  highest	  diabetes	  
mellitus	  prevalence	  also	  rated	  as	  high	  TB	  burdened	  countries.	  (14,16)	  People	  with	  diabetes	  











approximately	  2-­‐3	  times	  greater	  risk,	  than	  those	  without	  diabetes	  mellitus.	  This	  is	  
irrespective	  of	  geographical	  area	  or	  study	  design.	  (17)	  (18)	  The	  mechanisms	  	  by	  which	  
tuberculosis	  infection	  risk	  is	  increased	  in	  people	  with	  diabetes	  mellitus	  are	  not	  specifically	  
clear,	  but	  it	  is	  proposed	  that	  it	  hinders	  the	  functioning	  of	  immune	  system	  components	  
(phagocytes,	  monocytes	  and	  lymphocytes)	  and	  thus	  retards	  the	  body’s	  defence	  systems	  
against	  TB.	  This	  is	  similar	  to	  the	  mechanisms	  induced	  by	  HIV	  and	  thus	  the	  clinical	  
manifestations	  and	  presentations	  of	  TB	  in	  diabetes	  mellitus	  may	  be	  similar	  to	  those	  with	  HIV.	  
(17)	  	  
The	  association	  between	  cigarette	  smoking	  and	  TB,	  regardless	  of	  the	  type	  of	  smoke	  
exposure	  or	  TB	  outcomes,	  has	  been	  consistently	  demonstrated.	  Smokers,	  compared	  to	  those	  
who	  do	  not	  smoke,	  have	  an increased	  risk	  of	  	  having	  a	  positive	  tuberculin	  skin	  test	  (TST),	  of	  
having	  active	  TB	  and	  of	  dying	  of	  TB.(19) When	  considered	  in	  isolation,	  smoking	  is	  the	  top	  
cause	  of	  preventable	  death	  worldwide,	  with	  most	  deaths	  occurring	  in	  low	  to	  middle	  income	  
countries	  where	  TB	  prevalence	  is	  also	  high.(19) A	  mathematical	  modelling	  analysis	  
undertaken	  in	  2011	  predicted	  that	  smoking	  would	  cause	  an	  excess	  of	  18	  million	  TB	  cases	  and	  
40	  million	  TB	  deaths	  between	  2010	  and	  2050	  if	  the	  current	  smoking	  trend	  trajectory	  
continued.	  The	  model	  also	  anticipates	  the	  effect	  of	  smoking	  would	  increase	  the	  TB	  cases	  by	  
7%	  and	  the	  deaths	  by	  66%	  compared	  to	  models	  that	  did	  not	  account	  for	  smoking.	  (20)
These	  groups	  of	  people	  living	  with	  HIV,	  those	  with	  diabetes	  mellitus and	  those	  who	  smoke	  
cigarettes	  are	  at	  higher	  risk	  of	  developing	  TB	  than	  those	  without	  these	  additional	  influences	  
and	  thus	  warrant	  extra	  focusing	  of	  efforts	  in	  screening	  for	  and	  detecting	  TB.
Screening	  for	  TB	  
The	  global	  control	  of	  TB	  is	  guided	  by	  three	  main	  strategies	  proposed	  by	  the	  World	  Health	  
Organisation:	  finding	  and	  diagnosing	  cases	  and	  treating	  active	  disease,	  recognising	  latent	  
infection	  and	  treatment	  of	  latent	  infection,	  and	  vaccination	  against	  TB	  using	  the	  BCG	  
vaccine.	  However,	  treatment	  of	  latent	  infection	  is	  not	  practiced	  widely	  as	  standard	  
procedure,	  and	  BCG	  vaccination	  coverage	  is	  limited	  as	  it	  is	  poorly	  effective	  in	  the	  prevention	  












Case-­‐finding	  can	  be	  passive	  or	  active.	  Passive	  case-­‐finding	  relies	  on	  patients	  presenting	  with	  
symptoms	  of	  TB	  disease	  at	  health	  facilities	  where	  they	  are	  then	  screened,	  diagnosed	  and	  
treated.	  Patients	  are	  essentially	  volunteering	  their	  symptoms	  to	  health	  care	  professionals.	  
(21)	  
Passive	  case-­‐finding,	  although	  currently	  the	  main	  mechanism	  for	  finding	  TB	  cases,	  is	  limited	  
by	  the	  fact	  that:	  
• a	  large	  percentage	  of	  people	  who	  have	  bacteriologically	  confirmed	  TB	  do	  not
experience	  symptoms	  for	  which	  they	  would	  consider	  seeking	  medical	  assistance	  and
so	  are	  missed	  cases;
• those	  who	  do	  experience	  some	  symptoms	  do	  not	  necessarily	  fulfil	  the	  criteria	  
required	  for	  further	  investigation	  and	  confirmation	  of	  TB	  (an	  estimated	  50-­‐60%	  of	  
bacteriologically	  confirmed	  TB	  cases	  did	  not	  fulfil	  the	  TB	  symptom	  screening criteria	  
of	  2	  to	  3	  weeks	  of	  cough);	  
• many	  persons	  with	  TB	  symptoms	  present	  at	  a	  late	  stage	  to	  health	  facilities	  and	  thus	  
remain	  infectious	  in	  the	  community	  for	  long	  periods	  of	  time;	  
• and	  passive	  case-­‐finding	  assumes	  that	  patients	  have	  good	  access	  to	  TB	  services which
is	  often	  not	  the	  case	  in	  high	  burden	  areas.(22)
Active	  case-­‐finding	  is	  proposed	  as	  a	  potential	  strategy	  for	  enhancing	  screening	  and	  detection	  
in	  the	  general	  population	  and	  high	  risk	  groups.(22) This	  is	  also	  known	  as	  intensified	  case-­‐
finding	  or	  provider-­‐initiated	  screening.	  	  It	  involves	  actively	  looking	  for	  tuberculosis	  by	  
screening	  in	  communities,	  and	  in	  high	  risk	  groups	  to	  detect	  new	  cases	  of	  TB	  that	  would	  
otherwise	  not	  be	  detected	  in	  the	  health	  facility	  and	  to	  detect	  cases	  earlier	  than they	  would	  
normally	  present	  to	  the	  health	  facility.	  	  Earlier	  initiation	  of	  treatment	  will	  prevent	  the	  
progression	  of	  disease	  and	  decrease	  the	  infectious	  period	  of	  an	  individual	  in	  the	  community.	  
(22,23)	  Mathematical	  models	  using current	  WHO	  strategies,	  show	  that	  active	  case-­‐finding
would	  have	  substantial	  benefits	  in	  the	  fight	  against	  TB.	  For	  example,	  active	  case-­‐finding
using	  symptoms	  screening	  of	  the	  entire	  general	  community	  every	  seven	  years	  could	  detect	  











programmes	  continue	  to	  expand,	  that	  there	  is	  capacity	  for	  further	  investigation	  in	  those	  
reporting	  symptoms,	  and	  that	  at	  least	  90%	  of	  those	  with	  active	  TB	  start	  treatment	  and	  attain	  
cure.(23)	  	  
Screening	  using	  symptoms	  
Symptom-­‐screening	  is	  the	  primary	  tool	  in	  active-­‐case-­‐finding	  for	  tuberculosis	  and	  this	  has	  
been	  shown	  to	  have	  a	  high-­‐yield	  	  especially	  where	  resources	  are	  limited	  and	  TB	  burden	  is	  
high.(21,24,25) Symptom	  screening	  implies	  that	  those	  who	  do	  not	  	  perceive	  that	  they	  have	  
symptoms	  of	  TB,	  and	  those	  who	  may	  perceive	  they	  have	  symptoms	  but	  do	  not	  have	  easy	  
access	  to	  TB	  services,	  are	  actively	  and	  systematically	  investigated	  depending	  on	  the	  rule	  of	  
the	  screening	  tool.(22) The	  simplest	  and	  most	  cost-­‐effective	  screening	  tool	  employed	  is	  a	  
symptom	  questionnaire,	  asking	  primarily	  about	  duration	  of	  cough,	  (	  more	  than	  two	  weeks),
but	  also	  coughing	  up	  blood,	  loss	  of	  weight,	  night	  sweats,	  fever	  	  and	  malaise.(26,25)	   Other	  
respiratory	  symptoms	  such	  as	  shortness	  of	  breath	  and chest	  pain	  may	  be	  considered.	  
Symptom	  screening	  is	  effective	  in	  detecting	  TB	  in	  primary	  health	  care	  settings.	  (27) However,
symptom	  screening	  may	  not	  be	  as	  effective	  during	  active	  case-­‐finding	  for	  TB.	  A	  community	  
survey	  conducted	  in	  2002	  in	  South	  Africa	  compared	  the	  TB	  case	  yield	  using	  active	  versus	  
passive	  case-­‐finding,	  employing	  a	  symptoms	  questionnaire	  as	  the	  tool.	  They	  found	  that	  
active	  case-­‐finding	  (ACF)	  using	  a	  symptom	  screening	  tool	  detected	  TB	  cases,	  but	  that	  cases
found	  in	  the	  community	  by	  active	  case-­‐detection	  were	  less	  symptomatic	  than	  those	  
presenting	  at	  the	  health	  facility	  in	  high	  burden	  areas.	  The	  figures	  presented	  showed	  that	  
41% (OR	  3.72,	  95%CI	  1.47-­‐9.34) of	  bacteriologically	  confirmed	  ACF	  cases	  did	  not	  cough,	  85%
(OR	  3.20,	  95%CI	  1.03-­‐9.93)	  of	  ACF	  cases	  did	  not	  have	  haemoptysis,	  59% (OR	  3.35,	  95%CI	  1.40	  
– 7.99)	  did	  not	  have	  night	  sweat,	  89%	  (OR	  4.28,	  95%CI	  1.21	  -­‐15.14)	  did	  not	  report	  fever	  and
56%	  (OR	  11.14,	  95%	  CI	  4.17-­‐29.74)	  did	  not	  report	  weight	  loss.	  (25)	  	  A	  similar	  study
conducted	  in	  two	  Zambian	  communities	  showed	  that	  many	  participants	  in	  the	  community
with	  bacteriologically	  confirmed	  TB	  did	  not	  meet	  the	  criteria	  for	  TB	  according	  to	  the
screening	  algorithm	  using	  classical	  TB	  symptoms.	  Only	  43%	  (N=79)	  met	  the	  criteria,	  with	  only











These	  and	  similar	  studies	  suggest	  that	  while	  symptom	  screening	  may	  not	  be	  sufficient	  to	  
detect	  all	  cases	  of	  active	  TB,	  as	  those	  detected	  in	  the	  community	  may	  be	  less	  symptomatic,	  
more	  sensitive	  screening	  	  tests	  may	  not	  be	  economically	  feasible	  or	  practical	  in	  poorly-­‐
resourced	  areas.	  (24,26,28,29)	  	  
Symptom	  screening	  in	  high	  risk	  groups	  
The	  efficiency	  of	  using	  TB	  symptom	  screening	  as	  a	  means	  of	  detecting	  TB	  has	  been	  
investigated	  in	  the	  high	  risk	  groups	  of	  people	  living	  with	  HIV	  but	  not	  those	  with	  diabetes	  
mellitus	  and	  smokers.	  TB	  symptom	  presentation	  may	  be	  different	  for	  each	  of	  these	  high-­‐risk	  
groups	  thus	  the	  symptom-­‐screening	  tool	  may	  need	  to	  be	  adapted	  for	  each	  these	  groups.	  
The	  WHO	  recommends	  collaborative	  TB/HIV	  activities	  such	  as	  “The	  Three	  I’s”	  (intensified	  
case-­‐finding,	  	  isoniazid	  preventive	  therapy	  and	  infection	  control)	  as	  part	  of	  the	  core	  TB	  and	  
HIV	  prevention	  strategy.(12) Intensified	  case-­‐finding	  involves	  actively	  screening	  for	  TB	  in	  HIV	  
positive	  individuals.	  Recent	  guidelines	  for	  provider	  initiated	  TB	  screening	  have	  been	  
developed	  following	  a	  large	  evidence	  base	  for	  TB	  symptom	  reporting	  in	  HIV	  positive	  
individuals.	  Traditional	  symptom	  screening	  of	  a	  cough	  for	  more	  than	  three	  weeks	  has	  been	  
shown	  to	  be	  insufficient	  for	  the	  detection	  of	  TB	  in	  people	  living	  with	  HIV,	  but	  may	  be	  useful	  
in	  reliably	  excluding	  TB	  when	  no	  other	  screening	  tests	  are	  available. (24,30) These	  and	  other	  
studies concluded	  that	  HIV-­‐infected	  adults,	  who	  have	  any	  one	  of	  the	  symptoms	  of	  current	  
cough,	  fever,	  loss	  of	  weight,	  or	  night	  sweats	  may	  have	  TB	  and	  should	  be	  investigated	  further.	  
Furthermore,	  they	  showed	  that	  in	  the	  absence	  of	  these	  symptoms,	  one	  could	  reliable	  
exclude	  TB	  in	  ART	  naive	  HIV-­‐infected	  clients.	  (31)(32) The	  negative	  predictive	  value	  (NPV)	  of	  
this	  screening	  rule	  was	  97%	  (	  95%	  CI	  97.4%-­‐98.0%)	  and	  90.0%	  (	  95%CI	  88.6%-­‐91.3%)	  at	  a	  TB	  
prevalence	  of	  5%	  and	  20%	  respectively	  in	  HIV-­‐positive	  people.	  (32) These	  results	  informed	  












Intensifying	  case	  detection	  among	  patients	  with	  diabetes	  mellitus,	  and	  screening	  for	  TB	  in	  
patients	  with	  diabetes	  mellitus	  	  on	  other	  indications	  besides	  symptoms	  is	  considered	  a	  high	  
priority	  by	  the	  WHO	  and	  forms	  part	  of	  the	  research	  agenda	  in	  the	  fight	  against	  TB.	  (34)(35)	  
The	  evidence	  base	  is	  not	  comprehensive	  enough	  for	  the	  development	  of	  a	  collaborative	  
diabetes	  mellitus	  and	  TB	  framework	  such	  as	  that	  for	  HIV.(34)	  There	  are	  key	  research	  
questions	  that	  remain	  unanswered,	  and	  that	  are	  necessary	  for	  the	  development	  of	  this	  
framework,	  among	  them,	  how	  to	  screen	  for	  TB	  in	  patients	  with	  DM,	  and	  whether	  the	  clinical	  
picture	  of	  TB	  is	  different	  in	  DM.	  (17,	  36,	  37)	  
The	  situation	  is	  similar	  with	  regards	  the	  effect	  of	  smoking	  on	  TB	  symptoms.	  (38)	  
e) Need	  for	  further	  research.
There	  is	  a	  paucity	  of	  evidence	  to	  guide	  the	  adaptation	  of	  screening	  tools	  using	  symptoms	  in	  
high	  risk	  groups	  for	  TB	  such	  as	  those	  with	  diabetes	  mellitus	  or	  those	  who	  smoke	  cigarettes.	  
As	  has	  been	  explored	  in	  the	  literature	  review, active	  case-­‐finding	  in	  the	  community	  using	  TB	  
symptom	  screening	  is	  a	  necessary	  strategy	  for	  employment	  in	  the	  fight	  against	  TB.	  Thus, the
literature	   review	   supports	   the	   need	   for	   the	   investigation	   of	   TB	   symptom	  manifestation in	  
persons	  living	  with	  HIV, with	  diabetes	  mellitus and	  smokers, as	  they	  are	  high-­‐risk	  groups for	  
tuberculosis.
Data	  	  collected	  during	  a	  large	  TB	  prevalence	  survey	  conducted	  in	  2010	  in	  24	  communities	  
across	  Zambia	  and	  the	  Western	  Cape	  South	  Africa,	  will	  be	  analysed	  to	  investigate	  the	  
prevalence	  of	  self-­‐reported	  symptoms	  of	  TB	  in	  cases	  with	  bacteriologically	  confirmed	  TB	  and	  
controls	  without	  TB	  disease	  stratified	  by	  HIV,	  diabetes	  mellitus	  and	  smoker	  status	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  of	  human	  immunodeficiency	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and	  hyperglycaemia	  on	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  in	  a	  
tuberculosis	  prevalence	  survey	  
Shahra	  Sattar1;	  Cari	  Van	  Schalkwyk2,	  Sian	  Floyd3,	  Peter	  Godfrey-­‐Fausset3,	  Donald	  A	  
Enarson1,	  David	  Coetzee4,	  Helen	  Ayles5,	  Nulda	  Beyers1	  on	  behalf	  of	  ZAMSTAR	  team	  
1Desmond Tutu TB Centre, Stellenbosch University, Cape Town, South Africa 2South African Centre	  for
Epidemiological Modelling and Analysis,	  University	  of	  Stellenbosch,	  Cape	  Town,	  South	  Africa 3London School of
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  Town, Cape	  Town, South Africa	  
5ZAMBART	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ABSTRACT	  
Setting: Tuberculosis prevalence	  survey conducted in 24	  high tuberculosis and human
immunodeficiency	  virus burden	  communities in	  Zambia and	  the Western Cape, South Africa.
Objective: To assess the effect of human immunodeficiency virus,	  hyperglycaemia, and smoking on
self-­‐reported tuberculosis symptoms.
Design and methods: Odds ratios and 95% confidence intervals were calculated for self-­‐reported TB
symptoms	  and smoking, human immunodeficiency virus (Abbot	  Determine HIV test), and/or	  
hyperglycaemia (finger-­‐prick glucose test) or self-­‐reported diabetes mellitus categorised by	  TB status	  
(confirmed through 16S DNA sequencing).
Results:	  Human	  immunodeficiency	  virus	  (OR	  3.17	  95%CI	  2.66-­‐3.87)	  and	  smoking	  (OR	  1.27	  95%CI	  
1.03-­‐1.58)	  are	  risk	  factors	  for	  tuberculosis.	  Hyperglycaemia	  showed	  no	  association.	  Tuberculosis	  
cases	  who	  smoke	  were	  less	  likely	  to	  report	  symptoms	  than	  non-­‐smoking	  cases	  (OR	  0.76	  95%CI	  0.54-­‐
1.07).	  Tuberculosis	  cases	  with	  human	  immunodeficiency	  virus	  were	  less	  likely	  to	  report	  any	  
symptoms	  compared	  to	  participants	  in	  South	  Africa	  (0R	  0.85	  95%CI	  0.64-­‐1.14)	  without	  human	  
immunodeficiency	  virus,	  but	  more	  likely	  in	  Zambia	  (OR	  6.25	  95%CI	  3.26-­‐11.97).	  Reporting	  1	  up	  to	  3	  
symptoms	  of	  cough,	  fever,	  night	  sweats	  or	  loss	  of	  weight	  had	  NPVs	  of	  60.3-­‐92.5%	  in	  smokers	  without	  
human	  immunodeficiency	  virus.	  	  
Conclusions:	  Smokers	  who	  do	  not	  report	  symptoms	  of	  cough,	  fever,	  night	  sweats	  or	  loss	  of	  weight	  























The	  prevalence	  of	  smoking,	  diabetes	  mellitus	  and	  human	  immunodeficiency	  virus	  (HIV)	  is	  
increasing	  in	  the	  high	  tuberculosis-­‐burdened	  areas	  of	  low	  to	  middle-­‐income	  countries.	  These	  
conditions	  are	  also	  risk	  factors	  for	  developing	  tuberculosis	  (TB).	  (1–5)	  
Tobacco	  smoking,	  the	  leading	  global	  cause	  of	  preventable	  death,	  has	  consistently	  been	  shown	  to	  
be	  associated	  with	  an	  increased	  risk	  of	  TB	  infection,	  disease	  and	  mortality.	  (3,6,7)	  Recent	  modelling	  
has	  suggested	  that	  should	  smoking	  trends	  continue	  along	  current	  trajectories,	  between	  2010	  and	  
2050	  smoking	  would	  produce	  over	  18	  million	  TB	  cases	  and	  40	  million	  TB	  deaths	  (8).	  	  
TB	  is	  more	  common	  among	  diabetic	  patients.(9) It	  is	  estimated	  that	  among	  the	  countries	  with	  the	  
highest	  TB	  burden,	  up	  to	  12.5%	  of	  incident	  TB	  cases	  will	  be attributable	  to	  diabetes	  mellitus	  (DM)	  
by	  2013,	  raising	  the	  potential	  for	  TB	  and	  DM	  syndemics.	  	  (10,11)However,	  there	  is	  limited	  
knowledge	  and	  experience	  on	  how	  to	  screen	  diabetic	  patients	  for	  TB	  in	  the	  most	  appropriate	  and	  
cost-­‐effective	  way.	  The	  convergence	  of	  the	  TB	  and	  diabetes	  mellitus	  epidemics	  motivates	  
operations	  research	  on	  the	  yield	  of	  intensified	  case-­‐finding	  among	  these	  patients.	  (10,12–15)
In	  people	  living	  with	  the	  human	  immunodeficiency	  virus	  (HIV),	  even	  in	  those	  on	  anti-­‐retroviral	  
therapy,	  TB	  is	  the	  leading	  cause	  of	  death:	  approximately	  25%	  of	  all	  AIDS	  deaths	  globally	  are	  due	  to	  
TB.	  Those	  living	  with	  HIV	  have	  between	  20	  and	  37	  times	  greater	  relative	  risk	  of	  TB	  than	  the	  rest	  of	  
the	  population.	  (4,16,17) However,	  traditional	  symptom	  screening	  of	  a	  cough	  for	  more	  than	  three	  
weeks	  	  has	  been	  shown	  to	  be	  insufficient	  for	  the	  detection	  of	  TB	  in	  those who	  are	  HIV-­‐infected.(18)
Guidelines	  for	  active	  TB	  screening	  specifically	  among	  HIV-­‐infected individuals	  have	  recently	  been	  
developed	  by	  the	  World	  Health	  Organisation	  and	  are	  being	  implemented	  by	  national	  TB	  
programmes.	  These	  guidelines	  recommend	  that	  adults	  and	  adolescents	  living	  with	  HIV	  who	  have	  
any	  one	  of	  the	  symptoms	  of	  current	  cough,	  fever,	  loss	  of	  weight	  or	  night	  sweats	  may	  have	  active	  
TB	  and	  should	  be	  evaluated	  for	  TB	  and	  other	  diseases.	  (19,20) No such evidence-­‐based	  guidelines	  
exist	  for	  clients	  with	  diabetes mellitus,	  and	  those	  who	  smoke. (11,13,21)
Passive	  TB	  case	  finding	  relies	  on	  patients	  volunteering	  symptom	  information,	  whereas	  active	  case-­‐
finding	  implies	  actively	  soliciting	  information	  and	  screening	  for	  tuberculosis.	  With	  the	  move	  
towards	  active	  case	  finding	  (especially	  in	  areas	  with	  a	  high	  TB	  burden	  and	  high	  prevalence	  of	  HIV,	  











symptoms	  can	  be	  used	  as	  a	  screening	  tool	  for	  people	  who	  are	  HIV-­‐infected,	  those	  who	  smoke	  or	  
have	  diabetes	  mellitus.	  	  
Our	  study	  aims	  to	  investigate	  the	  prevalence	  of	  self-­‐reported	  symptoms	  of	  TB	  in	  cases	  with	  
bacteriologically	  confirmed	  TB	  and	  controls	  without	  TB	  disease,	  stratified	  by	  HIV,	  DM	  and	  smoker	  
status,	  and	  identified	  during	  active	  case	  finding	  in	  a	  prevalence	  survey.	  We	  also	  aim	  to	  determine	  
the	  predictive	  values,	  sensitivities	  and	  specificities	  of	  individual	  symptoms	  and	  groups	  of	  symptoms	  
in	  determining	  TB	  in	  these	  risk	  groups.	  	  
METHODS	  
Study	  setting	  and	  participants	  
Data	  from	  a	  large	  household	  TB	  prevalence	  survey	  conducted	  in	  8	  communities	  in	  South	  Africa,	  and	  
16	  in	  Zambia	  in	  2010	  were	  utilised	  for	  analysis.	  This	  survey	  in	  high	  TB	  a d	  HIV	  burdened	  
communities,	  identified	  the	  prevalence	  of	  culture-­‐confirmed	  TB,	  the	  primary	  endpoint	  of	  the	  3-­‐
year	  community	  randomised	  intervention	  trial	  called	  ZAMSTAR	  (	  The	  Zambia	  South	  Africa	  TB	  and	  
AIDS	  Reduction	  study).(22) Geographical	  cluster	  sampling	  was	  used	  to	  randomly	  select	  census	  
enumeration	  areas	  and	  people	  who	  slept	  in	  all	  the	  houses	  in	  the	  selected	  enumeration	  areas	  were	  
eligible	  to	  participate	  in	  the	  prevalence	  survey.	  Adults	  (older	  than	  18	  years)	  were	  enrolled	  and	  gave	  
written	  informed	  consent.
Data	  collection
Trained	  research	  assistants	  recruited	  participants	  door-­‐to-­‐door	  in	  the	  community	  and	  administered	  
a	  questionnaire	  which	  obtained	  information	  regarding	  demographics,	  reporting	  of	  TB	  symptoms,
previous	  TB	  history,	  smoking	  history,	  diabetic	  status,	  HIV	  status	  regarding	  TB,	  and	  risk	  factors	  for	  
TB.	  Questions	  were	  read	  to	  participants	  and	  recorded	  using	  handheld	  electronic	  devices.	  	  
All	  participants	  were	  also	  asked	  to	  provide	  sputum	  samples	  for	  TB	  culture.	  Samples	  were	  kept	  in	  a	  
cool	  box	  and	  transported	  to	  the	  laboratory	  within	  48	  hours.	  Sputum	  smears	  were	  performed	  on	  all	  
samples	  and	  each	  of	  the	  sputum	  samples	  were	  inoculated	  onto	  2	  MGIT	  tubes.	  Spoligo-­‐typing	  was	  
performed	  to	  check	  for	  laboratory	  cross-­‐contamination	  on	  randomly	  selected	  positive	  samples	  
handled	  on	  the	  same	  day.	  All	  positive	  cultures	  were	  further	  processed	  by	  doing	  a	  Ziehl-­‐Neelson	  
smear	  for	  acid	  fast	  bacilli	  and	  by	  performing	  MPB64	  assays.	  Those	  samples	  that	  were	  positive	  on	  
ZN	  and	  PMB64	  were	  subjected	  to	  16sRNA	  sequencing	  to	  confirm	  Mycobacterium	  tuberculosis.	  











Participants	  were	  encouraged	  by	  the	  research	  assistants	  to	  consent	  to	  HIV	  counselling	  and	  testing	  
(HCT)	  and	  to	  have	  their	  glucose	  levels	  tested.	  HCT	  was	  performed	  either	  in	  the	  house	  or	  in	  a	  mobile	  
HCT	  tent	  in	  the	  community,	  and	  managed	  according	  to	  in-­‐country	  HCT	  guidelines.	  Individuals	  who	  
tested	  HIV-­‐positive	  on	  Abbot	  Determine	  HIV	  1/2	  test	  had	  a	  confirmatory	  test	  using	  Unigold.	  If	  the	  2	  
tests	  were	  discordant,	  a	  tie-­‐breaker	  was	  done	  in	  the	  health	  facility.	  
Rapid	  random	  blood	  glucose	  testing	  through	  the	  collection	  of	  a	  capillary	  blood	  sample	  was	  
performed	  in	  the	  homes	  of	  participants	  or	  in	  the	  mobile	  HCT	  tents	  using	  a	  glucometer.	  
Data	  variables	  and	  definitions	  
Symptom	  Reporting	  
Participants	  were	  asked	  to	  provide	  yes/no	  responses	  to	  questions	  regarding	  their	  symptom	  
experiences of current	  cough,	  chest	  pain,	  fever,	  night	  sweats,	  loss	  of	  weight	  and	  shortness	  of	  
breath.	  
Smoking	  
“Current	  smokers”	  at	  the	  time	  of	  the	  survey	  were	  determined	  via	  questionnaire.	  Participants	  who	  
answered	  “yes”	  to	  the	  question	  “have	  you	  ever	  smoked”	  and	  also	  answered	  that	  they	  had	  not	  
stopped	  smoking	  were	  defined	  as	  current	  smokers.	  
HIV	  
HIV	  positive	  participants	  were	  defined	  as	  those	  with	  a	  confirmed	  positive	  HIV	  rapid	  test	  result,
supplemented	  by	  the	  self-­‐reporting	  of	  HIV	  status	  for	  individuals	  who	  did	  not	  give	  a	  blood	  sample	  
for	  HIV	  testing.
Hyperglycaemia	  
Participants	  were	  defined	  as	  hyperglycaemic	  if	  a	  random	  capillary	  blood	  glucose	  was	  >11.1mmol/L	  
and/or	  if	  they	  self-­‐reported	  that	  they	  were	  diabetic.(23,24)	  
TB	  case	  
Study	  participants	  whose	  sputum	  samples	  were	  positive	  for	  Mycobacterium	  tuberculosis	  on	  16s	  












Data	  were	  analysed	  using	  the	  statistical	  analysis	  programme	  STATA	  12	  for	  Windows	  (StataCorp	  LP,	  
College	  Station,	  TX,	  USA).	  Odd	  ratios	  (OR)	  were	  calculated	  as	  a	  measure	  of	  association	  between	  
reported	  symptoms	  and	  the	  influence	  of	  HIV,	  smoking,	  and	  hyperglycaemia	  for	  both	  confirmed	  TB	  
cases	  and	  non-­‐TB	  cases.	  	  Odds	  ratios	  and	  their	  95%	  confidence	  intervals	  were	  calculated	  using	  a	  
robust	  standard	  errors	  logistic	  regression	  model	  that	  adjusts	  for	  clustering	  at	  a	  community	  level.	  	  
Interactions	  between	  TB	  and	  the	  influence	  of	  HIV,	  hyperglycaemia	  and	  smoking	  as	  well	  as	  
differences	  between	  the	  two	  countries	  in	  self-­‐reporting	  of	  symptoms	  were	  explored.	  	  Country	  of	  
residence	  ,	  age,	  sex,	  employment	  and	  education	  status	  were	  considered	  as	  possible	  confounders	  
The	  sensitivities,	  specificities	  and	  predictive	  values	  for	  TB	  in	  HIV	  positive,	  currently	  smoking	  and	  
hyperglycaemic	  participants	  were	  calculated	  in	  lieu	  of	  the	  screening	  rule	  developed	  by	  Getahun	  et	  
al.	  (19).	  	  
Ethics	  
Ethics	  approval	  for	  the	  ZAMSTAR	  prevalence	  survey	  was	  obtained	  from	  the	  University	  of	  Zambia	  
Research	  Ethics	  Committee	  and	  the	  London	  School	  of	  Hygiene	  and	  Tropical	  Medicine’s	  Ethics	  
Committee.	  Ethics	  approval	  for	  this	  study	  was	  obtained	  from	  The	  Human	  Research	  Ethics	  
Committee	  of	  the	  University	  of	  Cape	  Town	  and	  from	  the	  Ethics	  Advisory	  Group	  of	  the	  International	  
Union	  Against	  Tuberculosis	  and	  Lung	  Disease	  as	  part	  of	  TREAT	  TB.	  No	  name	  identifiers	  were	  used	  
during	  the	  collection	  of	  data	  during	  the	  ZAMSTAR	  TB	  Prevalence	  survey	  and	  participants	  were	  
assigned	  unique	  bar	  code	  identifiers.	  No	  names	  were	  linked	  to	  results	  during	  data	  extraction	  from	  
the	  locked	  ZAMSTAR	  database.
RESULTS	  
A	  total	  of	  123	  790	  participants	  were	  enumerated	  from	  all	  24	  sites	  and	  90	  601	  (73.2%)	  consented.	  
Of	  these	  26	  138	  were	  excluded	  (missing,	  or	  contaminated	  specimens),	  leaving	  a	  total	  evaluable	  
response	  of	  64	  463	  participants.	  The	  response	  rate	  was	  thus	  52.1%.	  894	  (1.4%)	  of	  the	  64	  463	  were	  
confirmed	  with	  TB,	  and	  529	  of	  these	  (59.2%)	  reported	  any	  TB	  symptoms.	  This	  is	  proportionally	  











Table	  1a:	  ZAMSTAR	  PREVALENCE	  SURVEY	  PARTICIPANT'S	  CHARACTERISTICS	  
Zambia(1)	   South	  Africa	  (2)	   Total	  
participants	   34446	  (53.4%)	   30017	  (46.6%)	   64463	  (100.0%)	  



















male	  (1)	   11546(33.7)	   92(47.9)	   10964(37.4)	   333(47.4)	   22510(35.4)	   425	  (47.5)	  
female	  (2)	   22708(66.3)	   100(52.1)	   18351(62.6)	   369(52.6)	   41059(60.6)	   469	  (52.5)	  
Age	  Categories	  
(y)	  
15-­‐24	   12124(35.4)	   45(23.4)	   8650(29.5)	   169(24.1)	   20774(32.7)	   214(23.9)	  
25-­‐34	   10047(29.3)	   82(42.7)	   8970(30.6)	   197(28.1)	   19017(29.9)	   279(31.2)	  
35-­‐44	   5154(15.0)	   42(21.9)	   5436(18.5)	   141(20.1)	   10590(16.7)	   183(20.5)	  
45-­‐54	   3142(9.2)	   12(6.3)	   373(1.3)	   107(15.3)	   6515(10.3)	   119(13.3)	  
55+	   3787(11.1)	   11(5.7)	   2886(9.9)	   88(12.6)	   6673(10.5)	   99(11.1)	  
Education	  
none	   1959(5.7)	   12(6.3)	   1099(3.8)	   40(5.70)	   3058(4.8)	   52(5.8)	  
primary	   10979(32.1)	   75(39.1)	   5522(18.8)	   189(26.9)	   16501(26.0)	   264(29.5)	  
secondary	   18389(53.7)	   98(51.0)	   21429(73.1)	   456(65.0) 39818(62.6)	   554(62.0)	  
tertiary	   2927(8.5)	   7(3.7)	   1265(4.3)	   17(2.4) 4192(6.6)	   24(2.7)	  
Employed	  
not	  employed	   21478(62.7)	   114(59.4)	   19709(67.2) 500(71.2)	   41187(64.8)	   614(68.6)	  
employed	   12776(37.3)	   78(40.6)	   9606(32.8) 202(28.8)	   22382(35.2)	   280(31.3)	  
Has	  symptoms	  
no	  symptoms	   23878(69.7)	   74(38.5)	   17899(61.1)	   291(41.5)	   41777(65.7)	   365(40.8)	  
any	  symptoms	   10376(30.3)	   118(61.5) 11416(38.9)	   411(58.5)	   21792(34.3)	   529(59.2)	  
Cough	  
no	   30338(88.6) 106(55.2)	   25683(87.6)	   469(66.8)	   56021(88.1)	   575(64.3)	  
yes	   3916	  (11.4) 86(44.8)	   3632(12.4)	   233(33.2)	   7548(11.9)	   319	  (35.7)	  
Fever	  
no	   32433(94.7)	   145(75.5)	   23929(81.6)	   522(74.4)	   56362(88.7)	   667(74.6)	  
yes	   1821(5.3)	   47(24.5)	   5386(18.4)	   180(25.6)	   7207(11.3)	   227(25.4)	  
shortness	  of	  
breath	  
no	   32224(9.4)	   151(78.7)	   26866(91.7)	   578(82.3)	   59090(93.0)	   729(81.5)	  











Cough	  was	  the	  most	  commonly	  reported	  symptom	  among	  TB	  cases	  (35.7%),	  followed	  by	  loss	  of	  weight	  
(31.2%)	  and	  night	  sweats	  (29.1%).	  266	  (29.8%)	  of	  TB	  cases	  reported	  3	  or	  more	  TB	  symptoms.	  	  
A	  total	  of	  221	  (24.9%)	  TB	  cases	  were	  HIV	  positive,	  121	  (13.5%)	  were	  current	  smokers,	  and	  58	  (6.5%)	  had	  
hyperglycaemia.	  The	  proportions	  of	  HIV	  positive	  cases	  and	  smokers	  were	  lower	  in	  non-­‐TB	  cases	  (12.1%	  and	  
8.5%	  respectively),	  and	  only	  marginally	  lower	  for	  hyperglycaemic	  non-­‐TB	  cases	  (5.2%).	  	  
TB	  cases	  and	  non-­‐TB	  cases	  comparisons	  were	  similar	  in	  both	  countries.	  There	  was	  a	  trend	  for	  less	  
prevalence	  TB	  in	  the	  more	  educated	  participants.	  (table	  1a).	  
Zambia(1)	   South	  Africa	  (2)	   Total	  
participants	   34446	  (53.4%)	   30017	  (46.6%)	   64463	  (100.0%)	  


















loss	  of	  weight	  
no	   29850(87.1)	   129(67.2)	   25172(85.9)	   486(69.2)	   55022(86.5)	   615(68.8)	  
yes	   4404(12.9)	   63(32.8)	   4143(15.7)	   216(30.8)	   8547(13.5)	   279(31.2)	  
night	  sweats	  
no	   32281(94.2)	   150(78.1)	   24675(84.2)	   484(69.0)	   56956(89.6)	   634(70.9)	  
yes	   1973(5.8)	   42(21.88)	   4640(15.8)	   218(31.0)	   6613(10.4)	   260(29.1)	  
chest	  pain	  
no	   31428(91.8)	   140(72.9)	   26306(89.7)	   559(79.6)	   57734(90.8)	   699(78.2)	  
yes	   2826(8.3)	   52(27.1)	   3009(10.3)	   143(20.4)	   5835(9.2)	   195(21.8)	  
Number	  of	  
Symptoms	  	  
no	  symptoms	   23878(69.7)	   74(38.5)	   17899(61.1)	   291(41.5)	   41777(65.7)	   365(40.8)	  
1	  symptom	   6412(18.7)	   30(15.6)	   5162(17.6)	   125(17.8)	   11574(18.2)	   155(17.3)	  
2	  symptoms	   2332(6.8)	   27(14.1)	   3016(10.3)	   81(11.5)	   5348(8.4)	   108(12.1)	  
3	  symptoms	   950(2.8)	   30(15.6)	   1696(5.8)	   75(10.7)	   2646(4.2)	   105(11.7)	  
4	  symptoms	   424(1.2)	   6(3.1)	   916(3.1)	   67(9.5)	   1340(2.1) 73(8.2)	  
5	  symptoms	   200(0.6)	   17(8.9)	   443(1.5)	   44(6.3)	   643(1.0)	   61(6.8)	  
6	  symptoms	   58(0.2)	   8(4.2)	   183(0.6)	   19(2.7)	   241(0.4)	   27(3.0)	  
Hyperglycaemia	  
no	   26782(78.2)	   139(72.4)	   10035(34.2) 259(36.9)	   36817(57.9)	   398(44.5)	  
yes	   936(2.7)	   6(3.1)	   2343(8.0)	   52(7.4)	   3279(5.2)	   58(6.5)	  
missing	   6536(19.1)	   47(24.5)	   16937(57.8)	   391(55.7)	   23473(36.9)	   438(49.0)	  
current	  smoker	  
no	   31605(92.3)	   162(84.4)	   26545(90.5) 611(87.0)	   58150(91.5)	   773(86.5)	  
yes	   2649(7.7)	   30(15.6)	   2770(9.5)	   91(13.0)	   5419(8.5)	   121(13.5)	  
HIV	  	  
negative	   23930(69.9) 86(44.8)	   15147(51.7)	   302(43.0)	   39077(61.5)	   388(43.4)	  
positive	   4894(14.3)	   80(41.7)	   2882(9.8)	   143(20.4)	   7716(12.1)	   223(24.9)	  











Both	  HIV	  (OR	  3.17	  95%	  CI	  2.66-­‐3.87)	  and	  current	  smoking	  (OR	  1.27	  95%	  CI	  1.03-­‐1.58)	  were	  risk	  factors	  for	  TB	  
when	  controlling	  for	  age,	  sex,	  community	  and	  education.	  However,	  hyperglycaemia	  was	  not	  a	  significant	  risk	  
factor	  for	  TB	  (OR	  0.94,	  95%	  CI	  0.7	  –	  1.27)	  (Table	  1b).	  Hyperglycaemia	  was	  excluded	  from	  further	  analysis.	  
TB	  cases	  were	  less	  likely	  to	  report	  
any	  symptoms	  if	  they	  were	  current	  
smokers	  (OR	  0.76,	  95%	  CI	  0.54	  –	  
1.07),	  compared	  to	  non-­‐smokers	  
(Table	  2a).	  The	  effect	  of	  HIV	  on	  
symptom	  presentation	  in	  TB	  cases	  
varies	  markedly	  by	  country,	  with	  a	  
bigger	  effect	  seen	  in	  Zambia.	  This	  
was	  not	  the	  case	  with	  smoking.	  	  TB	  
cases	  with	  HIV	  were	  less	  likely	  to	  
report	  any	  TB	  symptoms	  in	  South	  
Africa	  (OR	  0.85,	  95%CI	  0.64	  –	  1.14),	  
but	  significantly	  more	  likely	  to	  
report	  their	  symptoms	  in	  Zambia	  
(OR	  6.25,	  95%	  CI	  3.26	  –	  11.97)	  
(Table	  2b).	  	  
Table	  1b:	  Risk	  factor	  association	  with	  TB	  outcome	  
Univariate	   Controlling	  for	  age,	  sex,	  education	  
OR	   P-­‐value	   95%	  CI	   OR	   p-­‐value	   95%	  CI	  
HIV	  
Zambia	   4.55	   <0.001	   3.35	   6.18	   4.18	   <0.001	   3.01	   5.81	  
South	  Africa	   2.54	   <0.001	   2.07	   3.11	   2.84	   <0.001	   2.30	   3.52	  
Both*	   2.91	   <0.001	   2.46	   3.44	   3.17	   <0.001	   2.66	   3.78	  
Current	  Smoker	  
Zambia	   2.21	   <0.001	   1.49	   3.27	   1.27	   0.287	   0.82	   1.98	  
South	  Africa	   1.43	   <0.001	   1.14	   1.79	   1.24	   0.085	   0.97	   1.59	  
Both*	   1.68	   <0.001	   1.38	   2.04	   1.27	   0.026	   1.03	   1.58	  
Hyperglycaemia	  
Zambia	   1.24	   0.614	   0.54	   2.80	   1.38	   0.448	   0.60	   3.19	  
South	  Africa	   0.86	   0.326	   0.64	   1.16	   0.84	   0.292 0.61	   1.16	  
Both*	   1.64	   0.001	   1.24	   2.16	   0.94	   0.707 0.70	   1.27	  
*also	  controlling	  for	  country
Table	  2a: Effect of smoking	  on	  symptom reporting	  by TB	  diagnosis (controlling	  for
age, sex	  and country)
TB	  cases	   Non	  TB	  cases	  
Current	  Smokers	   OR	   95% CI OR	   95%	  CI	  
any	  symptom 0.76 0.54	   1.07	   1.50	   1.14	   1.98	  
two or more 0.84 0.57	   1.25	   1.72	   1.30	   2.28	  
three or more 0.99	   0.61	   1.60	   1.90	   1.48	   2.44	  
four or more 0.68	   0.37	   1.26	   1.97	   1.47	   2.62	  
cough 1.06	   0.73	   1.54	   1.62	   1.29	   2.03	  
chest pain 0.57	   0.33	   0.99	   1.51	   1.26	   1.81	  
fever 1.07	   0.62	   1.84	   1.26	   0.90	   1.77	  
night sweats 0.85	   0.58	   1.24	   1.80	   1.42	   2.29	  
loss	  of	  weight 0.66	   0.47	   0.92	   1.60	   1.23	   2.09	  











The	  associations	  between	  risk	  factors	  and	  symptom	  presentation	  were	  different	  in	  non-­‐TB	  cases.	  
Participants	  were	  significantly	  more	  likely	  to	  report	  any	  TB	  symptoms	  if	  they	  were	  not	  a	  TB	  case	  but	  had	  
either	  of	  the	  risk	  factors	  of	  HIV	  or	  smoking.	  The	  effect	  of	  HIV	  on	  symptom	  reporting	  in	  non-­‐TB	  cases	  did	  not	  
differ	  by	  country	  (Tables	  2a	  and	  2b).	  
Current	  cough	  was	  the	  most	  common	  symptom	  reported	  among	  all	  TB	  cases	  regardless	  of	  additional	  
influences.	  The	  specific	  symptom	  reporting	  among	  smokers	  and	  HIV	  positive	  participants	  is	  variable.	  TB	  
cases	  who	  smoke	  were	  less	  likely	  to	  report	  loss	  of	  weight	  than	  non-­‐smoking	  TB	  cases,	  HIV	  positive	  cases	  
were	  more	  likely	  to	  report	  chest	  pain,	  cough	  and	  loss	  of	  weight	  than	  HIV	  negative	  TB	  cases.	  
Both	  TB	  cases	  and	  non	  TB	  cases	  are	  more	  likely	  to	  report	  symptoms	  if	  HIV	  positive	  compared	  to	  HIV	  
negative.	  	  Smokers	  who	  have	  TB	  are	  less	  likely	  to	  report	  symptoms	  than	  non-­‐current	  smokers,	  whereas	  
smokers	  who	  do	  not	  have	  TB	  are	  more	  likely	  to	  report	  symptoms	  than	  non-­‐current	  smokers.	  
Table	  2b:	  Effect	  of	  risk	  factors	  on	  reporting	  of	  symptoms	  by	  TB	  diagnosis	  and	  country.(Controlling	  for	  age	  and	  sex)	  
SOUTH	  AFRICA	   ZAMBIA	  
TB	  case	   Non TB Case TB	  case	   Non	  TB	  Case	  
HIV	  -­‐infected	   OR	   95%	  CI	   OR	   95%	  CI	   HIV	  -­‐infected	   OR	   95%	  CI	   OR	   95%	  CI	  
any	  symptom	   0.85	   0.64	   1.14	   1.39	   1.30	   1.49	   any	  symptom	   6.25	   3.26	   11.97	   1.66	   1.05	   2.67	  
two	  or	  more	   1.08	   0.83	   1.41 1.62	   1.40	   1.86	   two	  or	  more	   5.55	   2.80	   11.00	   2.04	   1.86	   2.25	  
three	  or	  
more	   1.18	   0.96	   1.44	   1.84	   1.53	   2.20	  
three	  or	  
more	   3.54	   1.73	   7.27	   2.52	   2.25	   2.82	  
four	  or	  more	   1.72	   0.93	   3.20	   2.06	   1.75	   2.43	   four	  or	  more	   2.00	   0.67	   5.94	   2.89	   2.31	   3.60	  
cough	   1.14	   0.78	   1.67	   1.56	   1.46	   1.67	   cough	   3.33	   1.72	   6.44	   1.81	   1.66	   1.98	  
chest	  pain	   1.48	   1.00	   2.18	   1.61	   1.48	   1.76	   chest	  pain	   1.63	   0.86	   3.10	   1.45	   1.30	   1.61	  
fever	   0.88	   0.60	   1.29	   1.25	   1.09	   1.43	   fever	   4.44	   1.60	   12.34	   1.88	   1.66	   2.13	  
night	  sweats	   1.10	   0.77	   1.58	   1.52	   1.30	   1.78	   night	  sweats	   3.54	   1.40	   8.97	   2.03	   1.77	   2.31	  
loss	  of	  
weight	   1.17	   0.72	   1.91	   1.75	   1.46	   2.10	  
loss	  of	  
weight	   4.71	   2.32	   9.57	   1.81	   1.51	   2.15	  
shortness	  of	  
breath	   1.32	   0.77	   2.24	   1.42	   1.26	   1.60	  
shortness	  of	  











We	  applied	  the	  Getahun	  symptom	  screening	  rule	  to	  determine	  sensitivities,	  specificities	  and	  predictive	  
values	  for	  TB	  in	  HIV	  positive,	  and	  currently	  smoking	  participants	  separately.	  (19)	  
Irrespective	  of	  HIV	  or	  smoking	  status,	  the
screening rule of 3 or more symptoms	  had
high	  specificities and	  NPVs. Specificities	  for
3	  or more	  symptoms ranged from 92.3%
to 97.2%, and 97.8% to 99.4% for	  NPVs.
There is almost no difference in NPVs and
specificities	  between 1 or more symptoms,
and 3	  or more	  symptoms across risk factor
status.
Sensitivities	  and	  PPVs	  were	  consistently	  
low	  across	  risk	  factor	  status	  and	  number	  
of	  symptoms	  reported	  except	  for	  current	  
smokers	  who	  are	  HIV	  negative,	  where	  
weight	  loss	  had	  a	  high	  sensitivity	  out	  of	  
keeping	  with	  other	  individual	  symptoms	  at	  
88%.	  When	  examined	  by	  country,	  
specificities,	  sensitivities,	  and	  predictive	  
values	  were	  similar.	  However,	  the	  
sensitivity	  of	  this	  screening	  rule	  was	  only	  
considered	  high	  in	  Zambia,	  among	  HIV	  
positive	  cases	  (81.3%).	  Specificities	  were	  
low	  across	  all	  risk	  factors	  by	  country	  
ranging	  from	  50.7%	  to	  66.7%.	  
Table	  3:	  	  Test	  characteristics	  of	  association	  of	  various	  symptoms	  with	  TB	  
in	  groups	  identified	  by	  the	  ZAMSTAR	  prevalence	  survey
OR	   NPV	   PPV	   Sens	   Spec	  
HIV	  negative	  39465	  (61.2%)
cough	  	   4.14	   99.3%	   2.9%	   34.8%	   88.6%	  
fever	   2.73	   99.2%	   2.3%	   24.2%	   89.5%	  
night	  sweats	   4.11	   99.2%	   3.1%	   29.6%	   90.7%	  
weight	  loss	   2.84	   99.2%	   2.2%	   29.6%	   87.1%	  
1	  or	  more	   3.17	   99.4%	   1.9%	   57.2%	   70.4%	  
2	  or	  more	   4.39	   99.3%	   3.1%	   34.0%	   89.5%	  
3	  or	  more	   7	   99.2%	   5.5%	   19.1%	   96.7%	  
HIV	  positive	  7939	  (12.3%)
cough	  	   3.7	   98.1%	   6.8%	   44.4%	   82.3%	  
fever	   2.77	   97.7%	   6.0%	   30.9%	   86.1%
night	  sweats	   2.9	   97.8%	   6.2%	   31.8% 86.2%	  
weight	  loss	   2.77	   97.9%	   5.5%	   42.6% 78.9%	  
1	  or	  more	   3.1	   98.5%	   4.6% 67.3%	   60.0%	  
2	  or	  more	   4.41	   98.2%	   7.4% 48.4%	   82.4%	  
3	  or	  more	   4.74	   97.8%	   9.8%	   26.5%	   92.3%	  
Non-­‐smoker	  (HIV	  –ve)	  	  
36484	  (56.6%)	  
cough	  	   4.57	   99.3%	   3.0%	   35.9%	   89.1%	  
fever	   2.96 99.2%	   2.3%	   25.4%	   89.7%	  
night	  sweats	   4.68	   99.3%	   3.3%	   30.6%	   91.4%	  
weight	  loss	   3.32 99.3%	   2.4%	   32.1%	   87.6%	  
1	  or	  more	   3.58	   99.5%	   1.9%	   59.2%	   71.2%	  
2	  or	  more	   5.06	   99.3%	   3.3%	   35.9%	   90.1%	  
3	  or	  more	   8.54	   99.2%	   6.2%	   20.4%	   97.1%	  
Smoker	  (HIV	  –ve)	  	  
2981	  (4.6%)	  
cough	  	   1.7	   98.70%	   2.3%	   26.7%	   82.4%	  
fever	   1.26	   98.50%	   1.8%	   15.6%	   87.3%	  
night	  sweats	   1.34	   98.60%	   1.9%	   22.2%	   82.4%	  
loss	  of	  weight	   0.54	   99.10%	   1.7%	   88.9%	   18.7%	  
1	  or	  more	   1.11	   98.60%	   1.6%	   42.2%	   60.3%	  
2	  or	  more	   1.18	   98.50%	   1.7%	   20.0%	   82.6%	  












In	  table	  1b	  we	  show	  that	  hyperglycaemia	  is	  not	  a	  risk	  factor	  associated	  with	  TB	  in	  this	  population,	  thus	  it	  
was	  not	  considered	  for	  further	  analysis	  in	  ascertaining	  symptom-­‐reporting	  likelihoods	  as	  there	  would	  be	  no	  
added	  benefit	  in	  this	  population.	  	  
Furthermore,	  we	  were	  limited	  in	  that	  participants	  were	  only	  offered	  a	  single,	  random	  blood	  glucose	  test.	  
This	  is	  not	  sufficient	  criteria	  to	  confirm	  a	  DM	  diagnosis,	  nor	  to	  make	  inferences	  regarding	  DM	  and	  TB	  
symptoms	  during	  analysis.	  A	  recent	  study	  conducted	  in	  Tanzania,	  showed	  that	  TB	  cases	  with	  confirmed	  DM	  
were	  less	  likely	  to	  report	  TB	  symptoms	  than	  TB	  cases	  without	  DM,	  but	  none	  of	  these	  were	  significant	  
results.(25)	  	  
TB cases who smoke are generally less likely to report their TB symptoms than TB cases who do not smoke.
However, screening for TB in people who smoke is still a valuable strategy as NPVs were high.
Thus utilising a	  screening	  rule	  similar to the	  one	  developed by the	  WHO for people	  living	  with HIV can
reliably exclude smokers from requiring further	  diagnostic testing.
In	  conjunction	  with	  confirmed	  evidence,	  we	  found	  that HIV is a large risk factor for tuberculosis.
Interestingly we found that	  
HIV positive TB cases in Zambia are much more likely to report any symptoms compared to HIV negative TB
cases, whereas	  they	  were less	  likely	  to report any	  symptoms	  in South Africa. This may be due to a	  difference
in	  perception	  of symptoms	  between South African and Zambian participants. Or, it	  could be argued that	  the
reason TB cases who are HIV positive are less likely to report	  their	  symptoms in South Africa is because of	  
better TB/HIV integration	  services; thus TB	  cases are diagnosed	  earlier and	  have less time to	  develop	  and	  
report	  their	  symptoms. However, the reporting of	  symptoms also depends on the stage of	  the disease in the
individual	  and	  the	  risk	  of	  TB	  is	  more	  likely	  in	  persons	  with	  a	  lower	  	  CD-­‐4	  count which we	  have	  not taken	  into	  
account in this study.(26)
Strengths	  and	  limitations	  
The	  ZAMSTAR	  prevalence	  survey	  was	  not	  designed	  to	  answer	  our	  research	  question	  and	  the	  initial	  response	  
rate	  was	  low.	  Furthermore	  the	  prevalence	  survey	  provided	  limited	  information	  on	  smoking,	  and	  we	  were	  
unable	  to	  confirm	  a	  formal	  diagnosis	  of	  diabetes	  mellitus	  based	  on	  the	  single	  random	  blood	  glucose	  level.	  
Thus,	  we	  were	  limited	  instead	  to	  perform	  the	  analysis	  with	  respect	  to	  hyperglycaemia	  with	  or	  without	  a	  












Almost	  half	  of	  the	  TB	  cases	  had	  missing	  data	  regarding	  hyperglycaemic	  status,	  with	  the	  largest	  proportions	  
coming	  from	  South	  Africa.	  	  A	  similar	  picture	  is	  seen	  regarding	  HIV	  status	  as	  almost	  a	  third	  of	  the	  TB	  cases	  
had	  missing	  HIV	  data,	  with	  three	  times	  the	  number	  of	  missing	  data	  coming	  from	  South	  Africa	  than	  Zambia.	  	  
Symptom	  outcomes	  recorded	  with	  HIV	  associated	  TB	  were	  very	  different	  between	  the	  two	  study	  countries,	  
limiting	  the	  ability	  to	  make	  conclusions	  from	  analysis	  of	  a	  country-­‐combined	  dataset.	  
Major	  strengths	  of	  the	  study	  are	  that	  these	  data	  provide	  a	  large	  sample	  of	  bacteriologically	  confirmed	  TB	  
cases	  who	  were	  detected	  outside	  of	  the	  health	  care	  system,	  and	  who	  have	  corresponding	  TB	  symptom,	  
smoking,	  hyperglycaemia	  and	  HIV	  information	  acquired	  before	  diagnosis.	  	  
CONCLUSION	  
TB	  cases	  who	  smoke	  are	  generally	  less	  likely	  to	  report	  symptoms.	  	  Screening	  this	  high	  risk	  group	  is	  
worthwhile	  as	  if	  they	  do	  not	  report	  the	  symptoms	  of	  cough,	  fever,	  night	  sweats	  or	  weight	  loss,	  can	  reliably	  
be	  excluded	  from	  needing	  further	  diagnostic	  testing.	  	  Further	  investigation	  into	  the	  TB	  symptom	  reporting	  in	  
diabetic	  patients	  is	  warranted.	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